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Preface 
Nanomaterials are defined as the production of matter with at least one dimension ranging between 
1 and 100 nanometers. Due to the very small size and the resulting high surface/volume ratio, 
nanomaterials have physical-chemical properties that differ from those of macroscopic materials. 
Nowdays nanomaterials are often applied in many industrial fields including electronics, optics,  
textile and many others till to biomedicine [1]. 
The use of nanoparticles (NPs) in medicine has expanded recently, especially in diagnostic [2]. 
Actually nanoparticles could be designed as contrast agents or nanocarriers able to bind, specifically 
transport biomolecules and accumulate to the site to treat. 
 
Chapter 1 Introduction 
1. Different types of nanoparticles 
Different types of NPs are most used in the medical field. The nanoparticles can be classified into 
two main groups: organic and inorganic nanoparticles. 
 
1.1 Organic nanoparticles 
Organic nanoparticles can be defined as particles composed of organic compounds, mainly lipids or 
polymers [3]. They are often designed as liposomes, conjugated polymers, micelles, polymeric NPs, 
dendrimers, or carbon nanotubes. Sometimes they are derived from virus capsides. They are used as 
colloids to carry drugs or genes, to coat materials or as templates in various manufacturing 
processes [3]. The most common nanoparticles of organic origin used as drug delivering carriers are 
liposomes, micelles and polymer conjugates. 
 
1.1.1 Liposomes 
Liposomes are lipid vesicles of spherical shape, consisting of a double membrane structure 
composed of amphiphilic lipid molecules, with an average diameter between 50 and 500 nm [4]. 
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Their structure is characterized by an external phospholipid bilayer and an aqueous phase core 
which contain hydrophilic substances [4]. 
 
1.1.2 Micelles 
Micelles are nanoparticles formed by supramolecular self-assembly of surfactants and lipids [5]. 
The assembly principle of micelles formation is the hydrophobicity of the amphiphilic molecules in 
water, generating colloidal aggregates of these molecules. In general, micelles are colloidal particles 
formed by detergents and soaps [6]. Micelle formation needs to be started to have a minimum 
concentration of surfactant. In the initial formation phase, micelles show spherical shapes and their 
dimensions increase with the addition of more amount of surfactant [7]. 
 
1.1.3 Polymer conjugates 
Polymer conjugates are hydrophilic hybrid structures consisting of polymer chains covalently 
bound to a drug or a protein. Polymer conjugates correspond to drug molecules or bioactive 
molecules that can be linked to a macromolecule through a spacer molecule, which can incorporate 
a breaking point to allow the release of the drug at the target site [8]. A high percentage of the 
applications of polymer conjugates are in the therapeutic and nanomedical field [9]. 
 
1.1.4 Dendrimers 
Dendrimers are repetitively highly branched, star-shaped monodispersed macromolecules with 
nanometer-scale dimensions that emanate radially from a central core [10]. Dendrimers are defined 
by three components: a central core, an interior dendritic structure (the branches), and an exterior 
surface with functional surface groups [10]. In the biomedical area, dendrimers had been used for in 
vitro diagnosis, as contrast agents in magnetic resonance imaging when conjugated with other 
molecules, as drug delivery systems, in gene therapy as vectors to transfer genes through the cell 
membrane, and in regenerative medicine [11-16].  
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1.1.5 Polymeric Nanoparticles 
Polymeric nanoparticles are by far the most studied organic particles. Polymeric NPs, also known as 
polymeric nanospheres, are usually defined as submicron-sized solid polymer particles with matrix 
type structure, in which a cargo can be encapsulated within the polymer matrix or absorbed in the 
surface [17]. Polythiophenes, polyfluorenes, poly(p-phenylenevinylene)s, and poly(p-
phenyleneethynylene)s derivatives are polymeric NPs that can be used for electro-optical and 
photoluminescence applications [18, 19].  
 
1.2 Inorganic nanoparticles 
This category include nanoparticles with different chemical origin whose composition are not based 
only on C, O N, and H chemistry. The nanoparticles of metallic origin are excellent candidates both 
in the diagnostic field, as contrast agents in MRI (Magnetic resonance imaging), and 
therapeutically, such as for drug delivery. 
1.2.1 Gold nanoparticles 
Gold nanoparticles (GNPs) are inorganic NPs that could be used as a promising tool for different 
biological applications thanks to their size- and shape-dependent physical properties. GNPs are 
pretty inert, mostly biocompatible, and almost easy to be functionalized and synthesized  [20, 21]. 
GNPs are used due to their unique optical-electronics properties in high technology applications 
such as organic photovoltaics, sensory probes, therapeutic agents, drug delivery, electronic 
conductors and catalysis. The optical and electronic properties of gold nanoparticles are tunable by 
changing the size, shape, surface chemistry, or aggregation state [22].  In fact, the size of spherical 
gold nanoparticles (AuNPs) influences their ability to enhance the response of optical sensors based 
on surface plasmon resonance (SPR) [23]. Thus, GNPs are a very promising candidate for 
biological imaging techniques. 
1.2.2 Quantum dots 
Quantum dots (QDs) are colloidal nanometre-sized crystals of semiconductor materials that are 
small enough to exhibit quantum mechanical properties [24]. The electronic properties of QDs are 
intermediate between those of bulk semiconductors and discrete molecules [25]. Smaller quantum 
dots (2 nm) present blue fluorescence emission (380-440 nm), while larger particles (5 nm) have red 
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fluorescence emission (605-630 nm) [26]. QDs have many advantages in respect with the most 
common organic dye molecules. QDs are robust and stable light emitters thanks to their inorganic 
makeup and are not so susceptible to photobleaching than organic dye molecules. This 
photostability makes very useful in observing cells for a long period of time [26, 27]. Different 
surface modifications of QDs were achieved to visualize labelling of whole cells and tissue sections 
[28, 29]. Quantum dots can be employed such as delivery and reporter systems in transfection 
therapies in vivo. 
 
1.2.3 Magnetic nanomaterials  
Magnetic materials include various materials and are classified according to their chemical origin, 
crystallographic configuration and magnetic properties. Magnetic nanoparticles (MNPs), consisting 
of magnetic elements (iron, cobalt, nickel oxides), are of great interest, particularly in biomedicine 
fields. The use of iron oxide nanoparticles in biomedical research is progressively gaining a lot of 
importance, with the purpose to develop new types of functionalized and biocompatible magnetic 
nanoparticles. Different types of iron-oxide nanoparticles can be produced, such as hematite (α-
Fe2O3), maghemite (γ-Fe2O3) and magnetite (Fe3O4), among which the latter could be very 
interesting for different biomedical applications [30].  
Susceptibility to magnetic fields is a criterion to classify magnetic materials into diamagnetic 
materials which have a weak repulsion from an external magnetic field corresponding to a negative 
susceptibility, paramagnetic materials showing small and positive susceptibility, and ferromagnetic 
materials which have a large and positive susceptibility to magnetic fields [31].   
Superparamagnetism of iron oxide particles is a prerequisite to MNP use, as well as an underlying 
reason for its limitations. Superparamagnetism gives the possibility to magnetize the nanoparticles 
by an external magnetic field. This property is highly useful especially in biomedicine [32]. The 
limit volume to have superparamagnetic nanoparticles at a certain temperature is related to the 
magnetocrystalline anisotropy. Iron-oxide nanoparticles have superparamagnetic properties 
although they have larger dimensions compared to any other magnetic metal [32]. Magnetic 
nanoparticles have the unique ability that can be directed under the influence of an external 
magnetic field. Each magnetic particle can be considered similar to a single magnetic domain that 
shows superparamagnetic behavior when its size is below 10-20 nm and when the temperature is 
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above the so-called blocking temperature [33]. An important property of iron-oxide nanoparticles is 
the loss of their magnetization when the magnetic field is switched off.  
 
1.2.4 Cobal ferrite 
Cobalt ferrite nanoparticles are used in hyperthermia treatment, since in nanosized state, cobalt 
magnetic moment relaxes much slower than in magnetite or maghemite nanoparticles with similar 
size [34, 35]. Cobalt ferrite (CoFe2O4) is a hard magnetic material with multiple properties: large 
magnetic anisotropy, high coercivity, high Curie temperature, large magnetostrictive coefficient, 
moderate saturation magnetization with good mechanical hardness and chemical stability [36, 37]. 
Moreover the saturation magnetization of cobalt ferrite is almost the same as magnetite but its 
crystalline anisotropy is one order of magnitude larger, making it suitable for hyperthermia 
treatment [38]. 
 
1.2.5 Manganese ferrite 
The MnFe2O4 has a structure with excellent properties such as high resistivity, high saturation 
magnetization, high initial permeability compared to the other ferrites [39]. The magnetic 
susceptibility of MnFe2O4 nanoparticles is higher respect to other ferrite nanoparticles such as 
Fe3O4, CoFe2O4 and NiFe2O4 [40]. MnFe2O4 nanoparticles could be used as novel MRI contrast 
agents [41]. MnFe2O4 MNPs have a greater biocompatibility and a strong phase contrast for 
magnetic resonance imaging in comparison with Fe3O4, γ-Fe2O3, CoFe2O4, and NiFe2O4 MNPs. 
Thus, MnFe2O4 MNPs can provide the multiple functionalities of imaging, hyperthermia and 
triggered drug release [42]. 
 
1.2.6 Zinc doped ferrites 
Zinc oxide is commonly used as additive in ferrites. It can improve the properties and drive the 
medical applications of ferrite-based nanoparticles [43, 44]. Zinc oxide increases the saturation of 
magnetization in small amounts [45]. 
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1.3 Methods of production of iron-oxide nanoparticles 
The most common synthesis strategies for the preparation of iron-oxide nanoparticles are: 
1) Wet chemical preparation methods, such as sol-gel synthesis, oxidation method, chemical co-
precipitation, hydrothermal reactions, flow injection synthesis, electrochemical method, 
aerosol/vaporphase method, sonochemical decomposition reactions, supercritical fluid method, and 
synthesis using nanoreactors [46-48]. 
2) Physical methods, such as gas-phase deposition and electron beam lithography. These methods, 
however, do not allow to control the particle sizes down to the nanometer scale [49, 50]. 
3) Microbial methods, these methods allow efficient and effective control on the composition and 
the particle geometry of the resulting material [51]. Diverse microorganisms belonging to 
prokaryotes are able to synthesize iron-oxide nanoparticles, e.g. Clostridium acetobutylicum [52, 
53]. The synthesis of nanoparticles may be intracellular or extracellular. The size and shape of the 
nanoparticles vary with the organism employed and conditions employed during the synthesis 
which included pH, temperature and substrate concentration [52]. 
 
1.4 Biomedical applications of magnetic nanoparticles 
Magnetic nanoparticles can be used for a variety of biomedical applications: 1) Transport and 
pharmacological release of drugs on specific sites, drug targeting; 2) Gene delivery systems; 3) 
Hyperthermia; 4) Tissue engineering and repair; 5) Diagnosis by Magnetic resonance imaging 
(MRI); 6) MRI-guided therapeutic cell replacement; 7) Theranostics; 8) Biochemical separations; 9) 
Immunoassay platforms; 10) Bioanalysis; 11) Magnetofection for target cancer gene therapy [54-
57]. 
Magnetic nanoparticles could play a key-role in the treatment of tumors, using two different 
approaches: 1) targeted drug delivery in the cancer site and 2) cancer magnetic induction 
hyperthermia in which an alternating magnetic field is used to heat up magnetic nanomaterials and 
hereby destroy targeted cancer cells [58-60].   
In this regard, iron-oxide nanoparticles with magnetic properties are one of the most suitable 
devices to achieve biomedical applications listed above. 
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1.5 Cytocompatibility of nanoparticles 
The safety of nanoparticles (NPs) in biomedical applications is a controversial issue. In the last 
years, the interest in nanotoxicology has increased and more studies regarding the cytotoxic 
properties of NPs have emerged [61-65]. The assessment of NP safety is related to a great variety of 
factors: (1) types of NPs, (2) stabilizing coating agents, (3) physicochemical parameters of the NPs, 
(4) incubation conditions (time and concentration), (5) type of cells used, (6) type of assay used [61-
68]. Surface coatings and particle size play a key-role for NPs-induced toxic effects, as they 
influence cellular responses, intensity of effects, and potential mechanisms of toxicity [65]. 
Numerous studies have demonstrated different toxic effects associated with exposure to 
nanomaterials, including mitochondrial damage, oxidative stress, chromosomal and oxidative DNA 
damage and altered cell cycle regulation [69-73]. Contact of the NPs with the cells may further 
affect the morphology, cytoskeleton, proliferation, differentiation, migration, and survival [64].  
 
1.6 Drug targeting 
The design of nanocarriers for drug delivery with selectivity to disease and anatomical sites has a 
great potential. For instance nanoparticle-conjugated drug and gene delivery systems could be used 
to treat neurological diseases using MNP-conjugated drugs to cross the blood-brain barrier [74, 75]. 
Nanotechnology for drug delivery can be used to achieve (1) site-specific delivery of drugs in tissue 
and organs; (2) improved delivery of poorly water-soluble drugs; (3) transcytosis of drugs across 
tight epithelial and endothelial barriers; (4) co-delivery of two or more drugs for combination 
therapy; (5) theranostic application of drug delivery by combining therapeutic agents with imaging 
modalities [76, 77]. The basic principles of magnetic targeting of MNP-conjugated drugs have been 
investigated experimentally. The surface hydrophilicity of MNPs plays a key-role for drug delivery. 
Targeted therapy using MNPs assembled with drugs was already tested in clinical trials as a cancer 
therapy [60]. Various studies investigated the biodistribution of MNPs through intravenous 
injection directed by an external magnetic field to concentrate MNPs at a specific target site; this 
procedure has been well tolerated in cancer patients [59, 60].   
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1.6.1 Passive and Active Drug Targeting 
There are two kinds of targeted drug delivery of nanocarriers: 1) active targeted drug delivery, that 
overcome the limitations of passive targeting by conjugation with affinity ligands (antibodies, 
peptides, aptamers, etc.) that recognize and bind to specific receptors on the target cell surface [78]; 
and 2) passive targeted drug delivery, such as the enhanced permeability and retention effect (EPR-
effect) that allows migration of molecules up to 50-100 nm in diameter into the target site [79]. In 
fact drug carriers are expected to stay in the blood for long time, accumulate in pathological sites 
with affected and leaky vasculature (tumors, inflammations, and infarcted areas) via the enhanced 
permeability and retention (EPR) effect, and facilitate targeted delivery of specific ligand-modified 
drugs and drug carriers into poorly accessible areas [80]. The active drug targeting increases the 
selectivity of the delivery of drugs [79]. Passive and active drug targeting with nanocarriers to 
disease or tumor site reduce toxic side-effects, increase efficacy, and enhance delivery of poorly 
soluble or sensitive therapeutic molecules [79]. 
 
1.7 Biosensor technologies 
A widespread application of MNPs is cell sorting, sometime streptavidin-coated magnetic beads for 
phenotypic selection of different cell types, including stem cells [81], lymphocytes, neuronal cells, 
etc [82, 83]. MNPs linked to monoclonal antibodies, could be used to purify blood from infective 
agents [84]. Moreover, MNP-based magnetic bioseparation could be applied for biosensor 
technologies (e.g detection of protein analytes using specific MNP-conjugated antibodies) [85]. 
 
1.8 Hyperthermia 
Hyperthermia is a very promising therapy for cancer that concentrates a localized heating above 43 
°C for about 30 min in the site of tumors [86]. Hyperthermia initiates a series of subcellular events 
in the tumor site, inducing various forms of damage including apoptosis, leading to subsequent cell 
death [87, 88]. Moreover, hyperthermia induce other effects in the tumor site such as enhancement 
of tumor blood flow, activation of immunological responses and oxygenation via greater vascular 
perfusion and permeability, and a shift toward anaerobic metabolism, all leading to an altered 
extracellular microenvironment [89]. MNPs are able to induce heat in the specific site of tumor 
under the influence of alternating magnetic fields due to energy reductions in the traversing of the 
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magnetic hysteresis loop [32]. Induction of heat is related to the magnetization properties of 
different types of MNPs and magnetic field parameters [30]. The functionalization of MNPs with 
silica coatings and other reactive chemical groups could improve the selectivity to tumors [90]. In 
fact, selectivity of magnetic nanoparticles uptake by tumors during hyperthermia therapy could be 
improved using MNPs conjugated with antibodies which target tumor-specific antigens or modified 
receptors [91].   
 
1.9 Magnetofection 
Another application of MNPs could be magnetofection to transfect permissive and non-permissive 
cells using MNPs associated to DNA vectors under external magnetic field influence [92]. In fact 
with this strategy a great increase in transfection performance for both non-viral and viral vectors 
was demonstrated [93]. 
 
1.10 Tissue Engineering 
Tissue engineering may have a great benefit by application of magnetic nanomaterials. In fact tissue 
engineering is useful to overcome the organ transplantation crisis, and thus create artificial organs 
and tissues [94]. To realize this objective similar architectures of in vivo organs should be replicated 
in vitro, in which the cells are allocated precisely. For this purpose, three-dimensional constructs 
(scaffolds or hydrogels) functioning similarly as under in vivo conditions should be firstly built up 
[95]. To allocate precisely cells into the three dimensional constructs magnetic force-based tissue 
engineering technique could be useful to provide magneto-responsive features to the cells and to 
achieve an efficient cell seeding and a controlled tissue assembly and complex tissue formation [96, 
97]. The inclusion of magnetic particles has no significant effect on the porosity, stability and 
wetting properties of the composite scaffolds, making them compatible for cellular support and 
cultivation [97]. 
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1.11 PhD thesis overview 
The overall goal of this PhD project was the biological characterization by in vivo and in vitro 
testing of magnetic nanoparticles that can be used for various applications. In recent years, 
considerable efforts have been spent to develop magnetic nanoparticles (MNPs) and improve their 
applicability in several areas [76]. Nanoparticles could open a new arena in the field of 
biomedicine. In fact, magnetite/maghemite nanoparticles combinations have already been approved 
for clinical use as MRI contrast agents [98]. Precise control over the synthesis conditions and 
surface functionalization of MNPs is crucial for their final physicochemical properties, colloidal 
stability, and biological behaviour/fate [60]. The aim of this work was to understand which of the 
synthesized magnetic nanoparticles could be more suitable to be used as a carrier or platform for 
various applications in different scientific fields.  
During this PhD program two different kinds of magnetic nanoparticles were developed: naked 
iron-oxide nanoparticles and silica or silica-based coated nanoparticles (core shell-type 
nanoparticles). The materials were synthesized at Politecnico di Torino - Laboratory of the Applied 
Science and Technology Department directed by Prof. Enrica Vernè. During this project three 
sequential syntheses of magnetic nanoparticles were developed. The concentration of the stock 
solutions of MNPs changed in the different syntheses of nanoparticles. The technology allowed to 
produce and gradually improve dispersibility, colloidal stability and biocompatibility of MNPs. 
Cytocompatibility assessment was performed using both direct and not-direct contact cytotoxicity 
evaluation with murine endothelial cells (MS1) both in static and dynamic conditions. ROS 
detection and apoptosis evaluation were also carried out to investigate influence of MNPs on these 
aspects. Murine endothelial cells were used for two reasons: 1) Endothelial cells are the first cell 
barrier that come in contact with MNPs intravenously injected; and 2) MS1 cells are involved in the 
stage of production and expansion of lentiviral vectors (transfection). In fact, MNPs could be used 
for applications of cancer gene therapy. Due to the formation of cluster of nanoparticles in static 
conditions, cytocompatibility of MNPs was also evaluated in dynamic conditions of cell culture. In 
fact, cells were seeded on polycaprolactone strips and cultivated under a continuous medium flow 
bioreactor to simulate blood stream. Then, in vivo biocompatibility and biodistribution of MNPs for 
7 days in mice was investigated after intravenous administration of MNPs via tail vein. Two doses 
of 2 and 20 mg/kg MNPs were separately given to the mice via tail vein injections. Hematological 
parameters, changes in serum and tissue iron levels were analyzed after 1 week of MNPs to mice. 
Experiment term of 7 days was chosen for biodistribution of MNPs. Tissue iron levels were 
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analyzed by ICP-AES and histological Perl’s Prussian Blue Staining. MNPs biodistribution 
evaluation was important to investigate the nanotoxicological effects of magnetic nanoparticles 
within tissues and organs. During the different cytocompatibility evaluation two concentrations of 
MNPs were standardized: 2 and 20 mg/kg body weight. In particular the concentration of 2 mg/kg 
body weight was found to be biocompatible and then suitable to be used as it is or as a nanocarrier 
for intravenous administration of drugs.   
 
Chapter 2 
Characterization of Mag and Mag-SiO2 nanoparticles synthesized via co-
precipitation method 
2.1 Aim 
The purpose of this part was to compare and optimize the development, production and 
cytocompatibility of iron oxide (Fe3O4) nanoparticles respect to the silica coated iron-oxide 
nanoparticles (SiO2-Fe3O4). A modified chemical co-precipitation method was used to prepare 
naked iron-oxide nanoparticles (Fe3O4), while silica coating was based on wet chemistry (Stöber 
method) and condensation of silica precursor tetraethyl orthosilicate (TEOS). The silica shell not 
only serves to protect nanoparticles from agglomeration but also assists further modifications so 
increasing their versatility and surface functionalization properties. Moreover it is durable in acid, 
and useful for the conjugation with biomolecules and for drug delivery. 
Silica is known to be one of the most suitable coating layer for superparamagnetic MNPs due to its 
chemical stability, biocompatibility [99] and versatility for surface modification. Moreover, it helps 
to convert hydrophobic NPs into hydrophilic water-soluble particles [100]. In addition, silica 
coating may provide flexibility in the construction of well-defined core-shell nanostructures.  
 
2.2 Materials and methods 
 
2.2.1 Synthesis of nanoparticles 
 
Two different types of magnetic iron-oxide nanoparticles (MNPs) were synthesized: pure magnetite 
(Mag) and silica-coated magnetite (Mag-SiO2) (Table 1). Magnetite nanoparticles were synthesized 
by co-precipitation method [101]: aqueous solutions 0,1 M of FeCl2 and FeCl3 were mixed to obtain 
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a stoichiometric ratio of Fe
2+
/Fe
3+
 of 1:2; subsequently NH4OH was added drop by drop under 
stirring, up to reach a pH value of about 10. The solution was placed in an ultrasound bath for 20 
min. After 24 hours magnetite nanoparticles were washed with bi-distilled water and redispersed 
always in water.  
The Mag-SiO2 nanoparticles were synthesized following the Stöber method [102]: 0,33 ml of 
tetraethyl orthosilicate (TEOS), 3 ml of water and 3 ml of ethanol were added to 40 ml of magnetite 
suspension, the pH of the solution was adjusted at 10 and the suspension was placed in orbital 
shaker at room temperature for 3 hours at 150 rpm. Then the Mag-SiO2 nanoparticles were washed 
with bi-distilled water and redispersed in water. All chemicals were purchased from Sigma Aldrich. 
The starting concentrations of MNPs were 4.9 mg mL
-1
 for Mag and 1.4 mg mL
-1
 for Mag-SiO2. 
Before use, the magnetic nanoparticles (Mag and Mag-SiO2) were sterilized by ultra-violet radiation  
for 60 minutes. 
 
2.2.2 Nanoparticle characterization  
 
Mag and Mag-SiO2 nanoparticles were characterized by means of transmission electron microscopy 
(TEM, Philips CM12, working at 120 kV operating voltage with a LaB6 filament), field emission 
scanning electron microscopy (FESEM - SUPRATM 40, Zeiss), scanning transmission electron 
microscopy (STEM-FESEM MERLIN Zeiss.) and energy dispersive spectroscopy (Edax PV9800). 
Selected area electron diffraction (SAED) patterns were obtained for each sample to observe the 
morphology and structure.  
FESEM micrographs of magnetic nanoparticles were captured using a SUPRATM 40, Zeiss field 
emission microscope (JEOL, Japan) operated at an excitation voltage of 10 kV. The elemental 
compositional study was investigated through energy dispersive spectroscopy (EDS) by using 
EDAX PV 9900 instrument coupled with STEM-FESEM.  
A droplet of an aqueous dispersion of nanoparticles was placed on a copper grid for FESEM, TEM 
and STEM-FESEM sample preparation, allowed to dry, and examined under electron microscopy 
previously cited. 
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SAMPLE MATERIAL MEDIUM Concentration 
of stock 
solution 
pH 
approx 
Notes 
Mag Magnetite 
nanoparticles 
PBS 4.9 mg/ml 7.70 Not stable in 
solution 
Mag-SiO2 
 
SiO2 coated magnetite 
nanoparticles 
PBS 1,4 mg/ml 7.22 Not stable in 
solution 
 
Table 1. Main characteristics of Mag and Mag-SiO2 NPs. 
 
2.2.3 Cell cultures 
 
Endothelial cell lines derived from mouse cells (MS1 - ATCC - CRL 2460) were used to evaluate  
cytocompatibility of nanoparticles. MS1 cells were cultivated in Dulbecco’s Modified Eagle 
Medium (DMEM, Sigma Aldrich) additioned with 2 mM L-glutamine, 10% FBS and 1% 
antibiotics/antimycotics (penicillin/streptomycin/gentamycin, Gibco). Cells were cultured at 
confluence in a humidified  5% CO2 atmosphere at 37°C. Afterwards murine endothelial cells were 
detached using 0.05% trypsin/EDTA solution (Sigma Aldrich) for five minutes. 
 
2.2.4 Not direct contact cytotoxicity evaluation 
 
Not direct contact cytotoxicity evaluation of MNPs was done using leaching solutions. These latter 
were obtained by adding MNPs to DMEM in a sterile closed tube at the concentration of 0.1 g/mL. 
Leaching conditions were 37°C for 24 and 72 hours according to ISO standard 10993-12: 1996. 
Then the specimens were centrifuged at 2500 rpm for 5 minutes and the supernatant was removed 
by suction and filtered through a microporous filter (0.22 µm) to provide the final eluating 
solutions. Afterwards, eluates were supplemented with 10% FBS and used to cultivate MS1 cells. 
Cells were seeded in a defined number (4x10
3
/well) into 96 wells plates (Cell Star, PBI 
International, Milan, Italy) and cultivated for three experimental time-points: 24, 48 and 72 hours  at 
37°C, in humidified 5% CO2 atmosphere. DMEM without any supplementation was used as a 
control. At each experimental time cells viability was evaluated by the (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide colorimetric assay (MTT, Sigma). Briefly, 100 μl of MTT 
solution (3mg/ml in PBS) were added to each sample and incubated 4 hours in the dark at 37° C; 
afterwards, formazan crystals were solved with 100 μl of dimethyl sulphoxyhde (DMSO, Sigma) 
and 50 μl were collected and centrifuged to remove any debris. Surnatant optical density (o.d.) was 
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evaluated at 570 nm using  a spectrophotometer (Spectra Count, Packard Bell, Meriden, CT, USA). 
The optical density of control sample was considered as 100% viability. Cell viability was 
calculated as follow: (indirect contact eluate o.d. / control o.d.)*100. Experiments were performed 
using four replicates at each experimental time. Furthermore, cells morphology was visually 
investigated at each experimental time by light microscopy (Leica AF 6500, Leica Microsystems) at 
20x magnification.  
 
2.2.5 Direct static contact cytotoxicity evaluation 
 
Direct static contact cytotoxicity evaluation of MNPs was done according to ISO standard 10993-5: 
2009. The cells were seeded in 24-well plates (1.6 x 10
4
 cells per well) in DMEM medium and 
cultured for 24 h at 37°C in 5% CO2 atmosphere-controlled incubator. After 24 hours the medium 
was substituted with a new one obtained by adding MNPs to DMEM to obtain the following 
concentrations: 10 μg/ml, 20 μg/ml, 40 μg/ml and 80 μg/ml (w/v).  
MS1 endothelial cells cultivated onto polystyrene wells in presence of DMEM additioned with 2 
mM L-glutamine, 10% FBS and 1% antibiotics/antimycotics  were used as control. Afterwards, cell 
viability was evaluated after 24, 48 and 72 hours using MTT assay, as above described for the 
indirect cytocompatibility assay. The viability of controls were considered as 100% viability. 
In addition, Trypan blue (TB) exclusion test of cell viability was used to assess the plasma 
membrane damage. The TB dye passes via the cell membrane of dead cells and thus stains the cells 
blue. The percentage of dead cells compared to control was determined. Briefly, the cells were 
seeded onto 24-well plates at a density of 1.6 x 10
4
 cells and cultivated as above described for 24h. 
After further 24-h, 48-h and 72-h exposure to DMEM additioned with MNPs at the concentrations 
of 10 μg/ml, 20 μg/ml, 40 μg/ml, 80 μg/ml, the culture medium with nanoparticles was removed 
and the cells were detached from the plate surface using trypsin/EDTA solution (0.25% trypsin and 
0.02% EDTA). Then, DMEM containing 10% FBS (1 ml) was added to each well in order to 
inactivate trypsin. The cells were stained with TB by mixing equal volumes of the cell suspension 
and 0.4% TB solution. The experiments were done in triplicate and repeated four time.   
 
2.2.6 Cells morphology evaluation by fluorescent microscopy 
Cells morphology after 24, 48 and 72 h in contact with MNPs at the concentrations above described 
was investigated by fluorescent microscopy (Leica AF 6500, Leica Microsystems, Basel, Switzerland). 
For the immunofluorescent (IF) staining the following procedure was used: cells were fixed with 4% 
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paraformaldehyde in PBS for 20 minutes at room temperature and then washed 3 times with PBS. 
Phalloidin (rhodamine B tetramethyl isothiocynate, 1/2000 in PBS, AbCam, Cambridge, UK) solution 
was added for 45 minutes at room temperature (RT) in order to investigate cells cytoskeleton; 
afterwards, the specimens were washed for further 3 times with PBS and co-stained with 4',6-
diamidino-2-phenylindole (DAPI, Sigma-Aldrich) to dye nuclei. Fluorescence images were acquired 
with a fluorescent microscope (Leica AF 1500, Leica Instruments). 
 
 
2.2.7 Reactive oxygen species (ROS) in cells 
 
The production of ROS in cells was measured using CellROX Oxidative Stress Reagents (Life 
Technologies) as an oxidation-sensitive probe. CellROX Oxidative Stress Reagents are fluorogenic 
probes designed to reliably measure reactive oxygen species (ROS) in live cells. CellROX Green 
Reagent is a DNA dye, and upon oxidation, it binds to DNA; thus, its signal is localized primarily 
in the nucleus and mitochondria. Briefly, 2.5 mM CellROX Green Reagent stock solution was 
diluted 500-fold with cell culture medium without serum or other additives to prepare a 5 µM 
working solution. MS1 cells were seeded in 12-well plates (7.5 x 10
4
 cells per well). After exposure 
to Mag and Mag-SiO2 NPs at the concentrations of 10, 20, 40 and 80 µg/ml for 24 h, the cells were 
washed with PBS and incubated in 1 mL of CellROX Green Reagent at a final concentration of 5 
μM at 37°C in the dark for 30 min. Experimental time-point (24 h) of ROS production induced by 
MNPs was chosen according to literature [103, 104]. Menadione (25 µM) was used as a positive 
control. Then, MS1 cells were analyzed with Flow cytometry (BD FACSCalibur) at an excitation 
wavelength of 485 nm for CellROX Green Reagent. Statistical data were obtained from the dot 
plots using CellQuest software (BD Biosciences).  
 
2.2.8 Statistical analyses 
All statistical analyses were performed using IBM Statistical Package for Social Sciences v. 20 
software (SPSS - IBM). Data were expressed as means ± standard deviations. The results were 
analyzed using one way analysis of variance (ANOVA) followed by Scheffe’s test, and P values 
less than 0.05 were considered to be statistically significant. 
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2.3 Results 
2.3.1 Nanoparticles: characterization 
 
In Figure 1, TEM images and SAED patterns of Mag and Mag-SiO2 nanoparticles are reported. It 
can be observed that both nanoparticles were spherical and the mean diameter was roughly 10-15 
nm. Diffraction patterns matched for magnetite [105]. In the case of Mag-SiO2 samples broad halos 
can be observed together with the diffraction signals characteristics of magnetite (that resulted a 
little attenuated), and can be attributed to the amorphous coating. 
In Figure 2, FESEM, TEM and STEM images of Mag-SiO2 sample are reported. FESEM confirms 
the spherical shape of particles with a diameter of about 10-15 nm. TEM and STEM observation 
showed the presence of a dense core (magnetite) covered by a less dense shell (silica) with a 
thickness of 1-2 nm. EDS analyses (spectra not reported for brevity) confirm the presence of iron 
(Fe) and oxygen (O) in the Mag sample and the appearance of the Si signal for Mag-SiO2 one. 
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Figure 1: TEM Images and SAED patterns of Mag and Mag-SiO2 samples. a) TEM image of Mag, b) SAED 
pattern of Mag, c) TEM image of Mag-SiO2, d) SAED pattern of Mag-SiO2. The numbers in SAED patterns 
refer to the distances of crystal planes of Mag and Mag-SiO2 NPs according to a defined crystallographic 
direction. 
 
 
 
 
 
Figure 2: FESEM (a), TEM (b) and STEM (c - dark field mode, d - bright field mode) images of Mag-SiO2 
NPs. 
 
 
2.3.2 Not direct contact cytotoxicity 
 
MTT assay demonstrated that the eluate solutions obtained by soaking magnetic nanoparticles in 
DMEM culture medium for 24 h showed a cell viability in a range of 66-73% and of 77-92% for 
Mag and Mag-SiO2 nanoparticles respectively (Fig. 3).   
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In a similar way the eluate solutions obtained by soaking MNPs in DMEM for 72 h showed cell 
viability in a range of 65-72% and of 78-92% for Mag and Mag-SiO2 nanoparticles respectively 
(Fig. 3).  
Trypan blue assay showed that the leaching solutions obtained from Mag nanoparticles in both 
soaking conditions showed higher cell mortality in a range of 28-35% (p < 0.05) after three 
experimental time-points compared to that observed for Mag-SiO2 NPs in a range of 8-23%. 
Trypan blue assay validated the results obtained with MTT assay (Tables 2 and 3). The differences 
were statistically significant (p < 0.05) at 24, 48 and 72 h time-point evaluations. No morphological 
alterations by microscopic observation were observed when cells cultivated with test media were 
compared with control ones (Figure 3).   
 
 
Not direct contact cytotoxicity (37°C for 24 h) Percentage 
of TB positive MS1 cells 
Samples 24 h 48 h 72 h 
Mag 26.4 + 1.2* 28.7 + 1.3* 31.1 + 0.9* 
Mag-SiO2 7.6 + 0.7 16.5 + 0.9** 22.4 + 1.2** 
 
Table 2. Trypan blue exclusion test. MS1 cell mortality after not direct contact with MNPs (37°C for 24 h). 
Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control and Mag-SiO2 
nanoparticles. **P < 0.05 compared with control. 
 
 
Not direct contact cytotoxicity (37°C for 72 h) Percentage 
of TB positive MS1 cells 
Samples 24 h 48 h 72 h 
Mag 27.6 + 1.1* 29.1 + 1.4* 32.5 + 1.6* 
Mag-SiO2 7.9 + 1.0 18.8 + 1.1** 21.9 + 1.3** 
 
Table 3. Trypan blue exclusion test. MS1 cell mortality after not direct contact with MNPs (37°C for 72 h). 
Data are shown as the mean ± standard deviation (n = 4).*P < 0.05 compared with control and Mag-SiO2 
nanoparticles. **P < 0.05 compared with control. 
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Figure 3. Not direct contact cytotoxicity evaluation of MNPs using murine endothelial cells (MS1 cells) and 
different eluates (24 and 72 h of soaking); MTT assay and optical microscopic images. Magnification: 20x, 
bar scale = 50 µm. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with 
control and Mag-SiO2 NPs. **P < 0.05 compared with control.  
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2.3.3 Direct contact cytotoxicity 
 
MS1 endothelial cells showed cell viability similar to that of control when put in direct contact with 
MNPs at the concentration of 10 µg/ml. Viability slightly decreased by increasing the 
concentrations of MNPs (20-80 µg/ml) for both Mag and Mag-SiO2 nanoparticles (Fig. 4). The 
same trend was observed at  all experimental time-points: 24, 48 and 72 hours (Fig. 5 and 6). 
Cell viability after contact with Mag-SiO2 NPs was in a range of 81-97% and not significantly 
differed when compared with Mag NPs (viability range between 86 and 98%) for concentrations 
ranging from 10 to 80 µg/ml (Figures 4-6). Trypan blue assay validated the results obtained with 
MTT assay (Tables 4-6).  
No morphological alterations were observed between cells in direct contact with MNPs and control 
using IF staining (Fig. 7-9) and microscopic observation (Fig. 10-12). 
 
 
 
 
Figure 4. Cytocompatibility assessment of MS1 cells after 24 hours in contact with different concentration 
of MNPs. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
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Table 4. Trypan blue exclusion test. MS1 cell mortality after direct contact of 24 hours with MNPs. Data are 
shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
 
 
 
Figure 5. Cytocompatibility assessment of MS1 cells after 48 hours in contact with different concentration 
of MNPs. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
 
 
Percentage of TB positive MS1 cells after 48 hours of contact with MNPs 
Samples 10 μg/ml 20 μg/ml 40 μg/ml 
 
80 μg/ml 
Mag 4.0 + 0.7 4.8 + 0.9 6.4 + 1.2 13.3 + 1.4* 
Mag-SiO2 5.9 + 0.9 8.5 + 1.4* 11.4 + 1.5* 16.9 + 0.8* 
 
Table 5. Trypan blue exclusion test. MS1 cell mortality after direct contact of 48 hours with MNPs. Data are 
shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
Percentage of TB positive MS1 cells after 24 hours of contact with MNPs 
Samples 10 μg/ml 20 μg/ml 40 μg/ml 
 
80 μg/ml 
Mag 1.7 + 0.9 4.2 + 1.5 5.8 + 0.7 12.6 + 1.2* 
Mag-SiO2 2.9 + 1.0 6.4 + 1.2 9.6 + 0.8* 14.7 + 1.4* 
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Figure 6. Cytocompatibility assessment of MS1 cells after 72 hours in contact with different concentration 
of MNPs. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
 
 
 
Percentage of TB positive MS1 cells after 72 hours of contact with MNPs 
Samples 10 μg/ml 20 μg/ml 40 μg/ml 
 
80 μg/ml 
Mag 4.3 + 1.4 6.2 + 1.3 7.9 + 1.0 14.3 + 1.1* 
Mag-SiO2 7.9 + 1.8 8.9 + 0.6* 13.6 + 1.3* 18.4 + 1.4* 
 
 
Table 6. Trypan blue exclusion test. MS1 cell mortality after direct contact of 72 hours with MNPs. Data are 
shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
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Figure 7. Cells seeded for 24 h in contact with nanoparticles (10-80 µg/ml). IF staining with DAPI (blue) 
and phalloidin (red). Magnification: 20x, bar scale = 50 µm. 
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Figure 8. Cells seeded for 48 h in contact with nanoparticles (10-80 µg/ml). IF staining with DAPI (blue) 
and phalloidin (red). Magnification: 20x, bar scale = 50 µm. 
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Figure 9. Cells seeded for 72 h in contact with nanoparticles (10-80 µg/ml). IF staining with DAPI (blue) 
and phalloidin (red). Magnification: 20x, bar scale = 50 µm. 
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Figure 10. Optical microscopic images of endothelial cells (MS1 cells) after direct contact with MNPs (10-
80 µg/ml) for 24 hours. Magnification: 20x, bar scale = 50 µm. No effects are observed on cell 
morphological features.  
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Figure 11. Optical microscopic images of endothelial cells (MS1 cells) after direct contact with MNPs (10-
80 µg/ml) for 48 hours. Magnification: 20x, bar scale = 50 µm No effects are observed on cell morphological 
features.  
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Figure 12. Optical microscopic images of endothelial cells (MS1 cells) after direct contact with MNPs (10-
80 µg/ml) for 24 hours. Magnification: 20x, bar scale = 50 µm. No effects are observed on cell 
morphological features.  
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2.3.4 ROS generation induced by MNPs 
 
Naked and silica core-shell type iron oxide nanoparticles could induce the generation of 
intracellular reactive oxygen species (ROS) depending on the concentration of nanoparticles, and 
oxidative stress followed by ROS generation may cause damage to mitochondria and DNA. We 
investigated whether Mag and Mag-SiO2 NPs could induce the generation of intracellular ROS. 
CellROX Green Reagent was used to determine the generation of intracellular ROS induced by 
MNPs. 
ROS generation was observed in MS1 cells exposed to Mag and Mag-SiO2 NPs at 10, 20, 40 and 80 
µg/ml concentrations for 24 h (Figure 13). An increase in ROS generation was observed in both 
Mag and Mag-SiO2 NPs in a concentration-dependent manner following the exposure of 10, 20, 40 
and 80 µg/ml MNPs for 24 hours (1.15%, 5.66%, 8.76% and 15.72% of ROS expression for Mag 
NPs and 2.11%, 20.78%, 22.64% and 24.13% of ROS expression for Mag-SiO2 NPs, respectively). 
All data were considered statistically significant (p < 0.05). 
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Figure 13. Effect of MNPs on the generation of ROS. Cells were treated with a designated concentration of 
MNPs for 24 hours. Results are expressed as mean ± SD. *P < 0.05 compared with control untreated and 
positive control (Menadione 25 µM). 
 
 
2.4 Discussion    
 
In this chapter we used a chemical co-precipitation method to synthesize magnetic nanoparticles. 
The advantages of this procedure include ease of synthesis, good control of chemical conditions, 
and repeatable experimental results [106]. Morphological observations and chemical compositional 
evaluation using EDS analyses and various electron microscopic methods confirmed that we 
successfully prepared naked and silica core-shell type iron oxide nanoparticles with uniform 
electron density, regular morphology, and homogeneous particle size, which are all fundamental 
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factors for biomedical applications. The bad points of this first synthesis of magnetic nanoparticles 
were the low dispersibility and colloidal stability of MNPs and a slight cell mortality observed for 
Mag NPs in not direct cytotoxicity. In vitro preliminary cytocompatibility is one of the most 
important prerequisite for the clinical application of any biomaterial [54]. The European Medicines 
Agency (EMA) and the U.S. Food and Drug Administration (FDA) are paying more attention to the 
safety of medical materials. Before any clinical study of a new biomaterial can take place, its 
compatibility must be evaluated by in vitro testing according to ISO standard 10993-12: 1996 that is 
a standard biological evaluation for medical instruments and is based on cell toxicity assays. The 
present study also carried out two cell toxicity tests based on mitochondrial dehydrogenase 
assessment (MTT assay) and plasma membrane damage evaluation (Trypan Blue (TB) staining). 
These cell toxicity assays are basic methods of evaluating the biocompatibility of biomaterials when 
studying cytotoxicity [54]. They are, fast, simple, flexible, and reproducible techniques. Therefore, 
we performed for MNPs a direct contact cytotoxicity evaluation and an in vitro not direct 
cytotoxicity test using a leaching solution. In not direct contact cytotoxicity evaluation Mag 
nanoparticles caused higher cell mortality after 24, 48 and 72 hours for both leaching conditions 
respect to Mag-SiO2 nanoparticles. Our results showed that Fe3O4/SiO2 magnetic nanoparticle 
leaching solutions have a very limited influence on cell viability.  
In direct static contact cytotoxicity evaluation a trend of cell viability comparable to control was 
observed after 24, 48 and 72 hours for both Mag and Mag-SiO2 nanoparticles. The cells maintained 
>80% cell viability even after 72 h of treatment with the samples at the concentration of 80 µg/ml. 
The trypan blue exclusion assays were also employed to determine the effect of iron-oxide 
nanoparticles on cell mortality of MS1 cells (Tables 3, 4 and 5). The obtained data were consistent 
with the results of the MTT assay. MTT assay and TB staining were used like two complementary 
tests for the evaluation of the cytocompatibility of magnetic nanoparticles constituting in this way a 
mutual confirmation of the experimental data. These results clearly confirmed the low cytotoxicity 
of the Mag and Mag-SiO2 NPs compared to control in direct static contact conditions. All cell 
viability rates of direct contact cytotoxicity were greater than 75%. Thus, it can be considered a 
promising cytocompatible biomaterial. ROS production induced from the first synthesis of MNPs 
on MS1 cells was investigated. ROS are important intracellular mediators of the inflammatory 
response and cell death following uptake of nanoparticles. ROS generation induced by the first 
synthesis of MNPs was in a concentration-dependent manner after 24 hours. 
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Chapter 3 
 
Biological characterization of magnetic nanoparticles synthesized via co-
precipitation methods using citric acid as dispersant 
 
3.1 Aim 
 
The purpose of this part was to improve dispersibility and cytocompatibility of naked and silica 
core-shell type iron oxide nanoparticles respect to the first synthesis of MNPs. Dispersibility of the 
second synthesis of MNPs was improved respect to the first synthesis using citric acid as dispersant. 
In addition, calcium-silica core-shell type iron-oxide nanoparticles were introduced between the 
magnetic nanoparticles produced to exploit their positive surface charge for MNPs functionalization 
with targeting moieties. The first synthesis of MNPs showed problems of dispersibility and 
colloidal stability. In fact MNPs of first synthesis were observed to precipitate in solution. Physical-
chemical, magnetic and in vitro biological characterization of the second synthesis of nanoparticles 
was carried out to investigate their colloidal stability, superparamagnetic properties and 
cytocompatibility.  
 
 
3.2 Materials and methods 
 
3.2.1 Nanoparticles preparation 
Four different types of magnetic nanoparticles were preapared: Mag, Mag-SiO2, Mag-SiO2-Ca(3), 
Mag-SiO2-Ca(17). The preliminary physico-chemical characterization of the nanoparticles was 
performed by Politecnico di Torino as following reported. Their main characteristics are described 
in table 7. One samples were naked magnetite while three consisted of a magnetite core covered by 
an amorphous silica shell (Mag-SiO2) (Figure 14). The silica or silica-based glass layer (e.g. SiO2-
CaO) is useful to increase NP surface reactivity (e.g. by exposition of hydroxyl groups) and allow 
functionalization with targeting moieties (e.g. folic acid, monoclonal antibodies, fatty acids), drugs 
(e.g. cisplatinum, doxorubicin) and lentiviral vectors or other drug/tracers. 
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Figure 14. Schematic representation of silica core-shell type magnetic nanoparticles. 
 
 
SAMPLE MATERIAL MEDIUM Concentration 
of stock 
solution 
pH 
approx 
Notes 
Mag Citric acid treated 
magnetite nanoparticles 
Water 5 mg/ml 4.12 Stable in 
solution for 
weeks 
Mag-SiO2 
 
SiO2 coated citric acid 
stabilized magnetite 
nanoparticles 
Water 1,4 mg/ml 6.96 Stable in 
solution for 
weeks 
Mag-SiO2-
Ca(3) 
SiO2 - Ca (low amount 
Ca) coated citric acid 
stabilized magnetite 
nanoparticles 
Water 1,3 mg/ml 7.10 Stable in 
solution for 
weeks 
Mag-SiO2-
Ca(17) 
SiO2 - Ca (high amount 
Ca) coated citric acid 
stabilized magnetite 
nanoparticles 
Water 2,6 mg/ml 8.01 Tendency to 
partial 
precipitation 
 
Table 7. Main characteristics of MNPs synthesized via co-precipitation methods using citric acid. 
 
3.2.2 Nanoparticles: synthesis of MNPs 
 
Magnetite nanoparticles (Mag) were produced by co-precipitation method [101] as explained in 
chapter 2.2.1. Aqueous solutions of FeCl2 and FeCl3 were mixed and pH was brought to basic 
values (about 10.0) by dropwise NH4OH addition.  
To improve water dispensability of the MNPs, a treatment of magnetite with citric acid was carried 
out by soaking nanoparticles in citric acid solution (0.05 M) for 24h and then exhaustively washed 
with water.   
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At the end of nanoparticles synthesis and fictionalization with citric acid, by adding tetraethyl 
orthosilicate (TEOS) (a silica precursor), with ethanol and water as solvent, an amorphous silica 
shell (Mag-SiO2) was obtained.  
To avoid the uncontrolled TEOS polymerization in the reaction media and to optimize the silica 
shell [107], the TEOS amount was reduced and concomitantly ethanol was added in the synthesis 
step, as described in the Stöber method [102]. 
To obtain calcium-silica magnetite NPs, calcium citrate was selected as precursor of Ca
2+
 ions and 
thus added in the synthesis process together with TEOS. Two different amounts of calcium citrate 
were tested to reach 99:1 (Mag-SiO2-Ca(3)) and 95:5 ((Mag-SiO2-Ca(17)) Si:Ca ratios, 
respectively. 
 
3.2.3 Nanoparticle characterization 
 
The size and shape of MNPs were characterized by means of transmission electron microscopy 
(TEM, Philips CM12, working at 120 kV operating voltage with a LaB6 filament), field emission 
scanning electron microscopy (FESEM - SUPRATM 40, Zeiss), scanning transmission electron 
microscopy (STEM-FESEM MERLIN Zeiss.) and energy dispersive x-ray spectroscopy (EDS) 
(Edax PV9800). Selected area electron diffraction (SAED) patterns were obtained for each sample 
to observe the morphology and structure.  
FESEM micrographs of magnetic nanoparticles were captured using a SUPRATM 40, Zeiss field 
emission microscope operated at an excitation voltage of 10 kV. The elemental compositional study 
was investigated through energy dispersive spectroscopy (EDS) by using EDAX PV 9900 
instrument coupled with STEM-FESEM.  
A droplet of an aqueous dispersion of nanoparticles was placed on a copper grid for FESEM, TEM 
and STEM-FESEM sample preparation, allowed to dry, and examined under electron microscopy 
previously cited. 
 
3.2.4 X-ray diffraction (XRD) analysis 
XRD analysis of the synthesized magnetic nanoparticles was carried out in D8 Advance Powder X-
ray diffractometer (Bruker, Germany) using CuKα radiation (λ = 1.54 nm). The XRD patterns were 
obtained between 2θ of 10° and 80° at a scanning rate of 4° min-1. The obtained pattern from the 
XRD analysis was used to identify the crystalline structure of the samples. 
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3.2.5 Magnetic performance testing 
 
A vibrating sample magnetometer (VSM-Lakeshore) was used to measure the magnetic hysteresis 
of naked iron-oxide nanoparticles and silica or silica-based glass layer core shell-type nanoparticles 
at 300 K under an applied field of ±15000 g. 
 
3.2.6 Determination of sedimentation rates 
 
Sedimentation tests were performed in order to evaluate the stability over time of iron oxide 
nanoparticles suspensions with and without different dispersants. The sedimentation rates of 
magnetic nanoparticles were measured by the change of optical absorbance with time, which can be 
related to the normalized nanoparticle concentration C/C0, where C is the concentration in time t, 
and C0 is the initial concentration (i.e. the initial absorbance at time 0). The sedimentation rate is 
then d(C/C0)/dt [108]. For relatively fast sedimentation conditions, the initial sedimentation rate was 
estimated from the decrease in the normalized particle concentration within the first 90 min, while 
for slower sedimentation conditions (C/C0 decrease less than 80% in 600 min), all data within 50 
hours were included. The following dispersants with the same concentration of MNPs (10 µg/ml) 
were used: citric acid, PEI (polyethylenimine), Dispex (polyacrylate dispersant) and Dolapix 
(deflocculant polycarboxylic acid). The tests were performed with and without the presence under 
the samples of a magnet for a period of time of 50 h.  
 
3.2.7 AFM/MFM 
 
AFM/MFM images of magnetic nanoparticles were acquired at room temperature with a Shimadzu 
Scanning Probe Microscope (SPM-9600). Tapping-mode was used to obtain the sample surfaces 
topography and lift-mode was used for the magnetic phase. In lift-mode, the tip-sample distance 
varied by tens to hundreds of nanometres. Magnetic force microscopy (MFM) images were 
obtained by allowing the cobalt coated magnetic tip (oscillating at its resonance frequency) to scan 
the air dried magnetic nanoparticles at the start height of 20 nm in 5 µm × 5 µm area using the 
MFM facility of Nanoscope IV. 
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3.2.8 Zeta potential 
 
Zeta potential of nanoparticles was detected using a laser-scattering method (Zetasizer Nano ZS90; 
Malvern Instruments, Malvern, UK). The nanodispersions were diluted 100-fold with deionized 
water before testing. The measurement was repeated three times per sample at room temperature 
and the values reported as the average ± SD. Zeta potential was measured to different acid and basic 
pH values to evaluate the colloidal properties of MNPs by varying the isoelectric point of MNPs 
solutions. 
Zeta potential can be related to the stability of colloidal dispersions. The relationship between the 
zeta potential value of the solution measured and the colloidal stability are indicated in Table 8 
[109]. 
 
 
Zeta potential [mV] Stability behavior of the colloid 
from 0 to ±5, Rapid coagulation or flocculation 
from ±10 to ±30 Incipient instability 
from ±30 to ±40 Moderate stability 
from ±40 to ±60 Good stability 
more than ±61 Excellent stability 
 
Table 8. Relationship between the value of Zeta Potential measured and colloidal stability of the solution 
[109]. 
 
 
3.2.9 Cell culture 
 
As previously described in the paragraph 2.2.2.  
 
3.2.10 Not direct contact cytotoxicity evaluation of MNPs 
 
As previously described in the paragraph 2.2.3.  
40 
 
3.2.11 Direct static contact cytotoxicity evaluation of MNPs 
 
Direct static contact cytotoxicity evaluation of MNPs was done according to ISO standard 10993-5: 
2009. Direct contact cytotoxicity was evaluated on MS1 cells for the following MNPs: Mag, Mag-
SiO2, Mag-SiO2-Ca(3) and Mag-SiO2-Ca(17). The cells were seeded in 24-well plates (1.6 x 10
4
 
cells per well) in DMEM medium and cultured for 24 h at 37°C in 5% CO2 atmosphere-controlled 
incubator. After 24 hours the medium was substituted with a new one obtained by adding MNPs to 
DMEM to obtain the following concentrations: 10 μg/ml, 20 μg/ml, 40 μg/ml and 80 μg/ml (w/v). 
MS1 endothelial cells cultivated onto polystyrene wells in presence of DMEM additioned with 2 
mM L-glutamine, 10% FBS and 1% antibiotics/antimycotics  were used as control. Afterwards, cell 
viability was evaluated after 24, 48 and 72 hours using MTT assay, as above described for the 
indirect cytocompatibility assay. The viability of controls were considered as 100% viability. Even 
for direct contact cytotoxicity evaluation the percentages of cell viability observed in MTT assay 
were validated by Trypan Blue (TB) staining. Furthermore, cells morphology was visually 
investigated at each experimental time by light microscopy (Leica AF 6500, Leica Microsystems) at 
20x magnification.  
 
 
 
3.2.12 Lactate dehydrogenase assay 
The effect of the NPs on the integrity of the cell membrane was assayed using a LDH Cytotoxicity 
Assay Kit (Gesan group). The assay was performed as per the manufacturer’s instructions. LDH is 
released by cells in response to damage or loss of integrity of cell membrane and is a cellular 
toxicity indicator. Briefly, 1.6 ×10
4
 cells/well were seeded in 24-well plates and treated with the 
following concentrations of MNPs: 10 μg/ml, 20 μg/ml, 40 μg/ml and 80 μg/ml (w/v) for 24, 48 and 
72 hours. Untreated cells were taken as the negative control and cells treated with lysis buffer were 
taken as the high control (total LDH in the cell). As a positive control, 1 μL of LDH was used to 
validate the assay. Following the incubation with NPs, the well plates were centrifuged at 600 g for 
10 minutes and 10 μL of the medium was transferred to a fresh 96-well plate. The medium was then 
incubated with 100 μL of LDH reaction mixture for 15 minutes at room temperature and the 
absorbance was measured at 450 nm using the microplate reader (Victor X4 - PerkinElmer) with the 
reference wavelength at 650 nm. LDH was quantified using the following formula:  
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LDH% =        Test – low control          x 100 
                High control – low control 
in which “low control” was the cells without any treatment and “high control” was the cells treated 
with lysis buffer (total LDH). 
 
 
3.2.13 Cells morphology evaluation by fluorescent microscopy 
MNPs influence on cell morphology and cytoskeleton was evaluated by immunofluorescence (IF) 
staining. MS1 cells morphology in contact with magnetic nanoparticles (40 μg/ml for 72 h)  was 
investigated by immunofluorescence (IF) staining. Briefly, after direct contact (72 h) with MNPs, cells 
were gently washed with PBS and fixed for 5 min with 4% formaldehyde-3% sucrose solution (in 
PBS) at RT. Afterwards, samples were washed three times with PBS and stained to visualize F-actins 
and nucleic acids by phalloidin (Molecular Probes Inc.) and 49,6-diamidino-2- phenylindole (DAPI, 
Molecular Probes Inc.). Fluorescence images were collected with a fluorescent microscope (Leica AF 
1500, Leica Instruments). 
 
 
3.2.14 Statistical analyses 
All statistical analyses were performed using IBM Statistical Package for Social Sciences v. 20 
software (SPSS - IBM). Data were expressed as means ± standard deviations. The results were 
analyzed using one way analysis of variance (ANOVA) followed by Scheffe’s test, and P values 
less than 0.05 were considered to be statistically significant. 
 
3.3 Results 
3.3.1 Physical-chemical characterization of MNPs 
 
Small (10-15 nm) Mag NPs were obtained as observable with Field Emission Scanning Electron 
Microscopy (FESEM) (Figure 15a). X-ray diffraction (XRD) patterns confirmed that they consisted 
of magnetite/maghemite (Figure 15b). Spherical silica coated magnetite nanoparticles, with an 
evident core-shell structure were obtained, as observed by TEM and scanning transmission electron 
microscope (STEM) (Figure 16). 
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A good dispersion was reached for magnetite (Fig. 17a), and less for SiO2-coated magnetite NPs 
(Figure 17b). Selected area electron diffraction (SAED) patterns detected signals of Mag NPs and 
Mag-SiO2 NPs (Figure 18). 
 
 
Figure 15. Magnetite obtained by co-precipitation a) FESEM observation, b) XRD analysis. 
 
 
Figure 16. TEM image (a), SAED (b) and STEM (c) of optimized SiO2 coated magnetite nanoparticles. 
 
 
 
Figure 17. a) citric acid treated magnetite nanoparticles, b) citric acid treated SiO2-coated magnetite 
nanoparticles. 
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Figure 18. SAED patterns of Mag NPs (a) and Mag-SiO2 NPs (b). 
 
 
3.3.2 Mag-SiO2-Ca NPs characterization 
 
In view of the fact that MNPs should be functionalized, their surface reactivity was enhanced. This 
aim was approached by adding calcium ions to their surface. Mag-SiO2-Ca nanoparticles (10-15 
nm) with calcium and with a good dispersion in water were obtained. An effective enrichment in 
Ca
2+
 was verified for both formulations with an increased calcium content, according to 
expectancies by means of compositional analysis (Figure 19).  
 
 
Figure 19. TEM image (a), SAED patterns (b) and EDS spectrum (c) of Mag-SiO2-Ca nanoparticles. 
 
 
3.3.3 Morphological observations 
 
TEM showed that the electron density of the magnetic particles was relatively high, and that the 
particles, which were spherical and partially agglomerated (Figure 20). Mag, Mag-SiO2, Mag-SiO2-
Ca(3) and Mag-SiO2-Ca(17) NPs obtained after citric acid (CA) treatment were analyzed for their 
size at transmission electron microscope (TEM) and shown to be small (10-15 nm) and spherical 
with a shell (silica) with a thickness of 1-2 nm (Figure 20). EDS analysis confirmed the 
composition of the nanoparticles through a rough estimate (data not shown). 
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Figure 20. TEM images of magnetic nanoparticles: Mag (A), Mag-SiO2 (B), Mag-SiO2-Ca3 (C) and Mag-
SiO2-Ca17 (D). 
  
 
3.3.4 Magnetic performance 
A vibrating sample magnetometer was used to measure the magnetic hysteresis of the magnetic 
nanoparticles at 300 K in an applied field of ± 15000 g. The results showed that the saturated 
magnetic intensity of Mag NPs and Mag-SiO2 NPs were ± 20.2 emu/g and ± 5.3 emu/g 
respectively. Instead, the saturated magnetic intensities were ± 7.3 emu/g and ± 7.4 emu/g for Mag-
SiO2-Ca(3) NPs and Mag-SiO2-Ca(17) NPs respectively (Figure 21). The four lines of the 
hysteresis loop overlapped, ie, no coercivity was noted, indicating that the magnetic nanoparticles 
prepared were superparamagnetic. 
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Figure 21. Measurement of the magnetic hysteresis of Mag, Mag-SiO2, Mag-SiO2-Ca(3), Mag-SiO2-Ca(17) 
NPs - Magnetic performance. 
 
3.3.5 AFM/MFM 
 
MFM images of magnetic nanoparticles along with its AFM image counterpart in 5 µm × 5 µm scan 
area were shown in the Figure 22. The image clearly indicated the core structure of magnetic 
nanoparticles. The dark contrasts appearing in the MFM image are the signals due to presence of 
iron oxide MNPs. Consequently, it is observed a high frequency change (up to 125 Hz) in the 
vertically oscillating magnetic tip nearby the surfaces of magnetic nanoparticles. The sample 
presents a relative constant magnetism all over the scanned MNPs surface regardless of the 
sample’s corresponding height. The relative intensity of the magnetic phase has a scale of 1°, 
indicating a weak detected field. The phase images shown in the right side of Figures present a 
magnetic response from the sample induced by the magnetization of the tip. The results here cannot 
be considered to be quantitative measurements because the principle of magnetic force microscopy 
(MFM) involves measuring a phase change in the resonance frequency spectrum of the 
(magnetized) cantilever, compared to the original resonance frequency while scanning different 
regions of the sample.  
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Figure 22. Representative AFM/MFM images of Mag, Mag-SiO2, Mag-SiO2-Ca(3) and Mag-SiO2-Ca(17) 
NPs with their respective size distributions. 
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3.3.6 Zeta potential evaluation 
 
Zeta-potential measurement is considered as a key parameter for providing an insight into the 
colloidal stability of the resulting magnetic nanoparticles. The zeta-potential results are shown in 
Fig. 23. The zeta potential of suspension for Mag NPs, Mag-SiO2 NPs, Mag-SiO2-Ca(3) NPs and 
Mag-SiO2-Ca(17)  NPs is - 32.46 mV, - 29.88 mV, - 42.21 mV and - 21.74 mV, respectively (Table 
9). Zeta potential measurements revealed an incipient colloidal instability for Mag-SiO2 NPs and 
Mag-SiO2-Ca(17) NPs, a moderate colloidal stability for Mag NPs and a good colloidal stability for 
Mag-SiO2-Ca(3) NPs. 
 
 
Figure 23. Zeta Potential measurements of MNPs. Data are shown as the mean ± standard deviation (n = 3). 
The black circles indicate starting pH of the solutions with MNPs.  
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Table 9. Zeta Potential measurements of MNPs. Data are shown as the mean ± standard deviation (n = 3). 
 
 
 
 
3.3.7 Sedimentation tests 
 
The sedimentation test showed the evolution of nanoparticles over a period of time of 48 h with and 
without the presence under the nanoparticles of a magnet. In the sedimentation test of MNPs 
without the presence of a magnet surnatant thickness decreased over time, while the thickness of the 
sediment increased (Figure 24). The suspension of MNPs with PEI was very unstable because the 
precipitation of the colloid was quicker even compared to the pure magnetite suspension. This was 
due because at pH around 8 this suspension of MNPs with PEI was close to isoelectric point and 
nanoparticles had not almost any surface charge. Samples with Dispex and Dolapix were very 
stable and only after one day they showed a sediment of 1 mm of thickness. Sample with citric acid 
did not show any sediment during the test time. This indicated high colloidal stability of the 
suspension of MNPs with citric acid (Figure 24). Test performed with the presence of a magnet 
under the samples showed a similar behavior, only faster. In fact with the presence of a magnet the 
suspension of MNPs with PEI was again the most unstable, because nanoparticles rapidly (few 
minutes) sedimented on the bottom of the tube and the surnatant was very clear. A similar behavior 
was also visible in the suspension of pure magnetite, dolapix and dispex, but they reached the 2 mm 
of sediment thickness in a slower way. In this case even the suspension with citric acid showed a 
little amount of sediment due to the presence of the magnet, but it was still the most stable 
suspension (Figure 25). The thickness of the sediment was different between the first and second 
test because the presence of the magnet made the sediment more compact, thus the thickness was 
lower in the second test. 
Sample Starting pH  ZP (mV) Stability behaviour of the colloid  
Mag NPs 4.19 - 32.46 ± 1.61 mV  Moderate stability 
Mag-SiO2 NPs 5.87 - 29.88 ± 1.42 mV  Incipient instability 
Mag-SiO2-Ca(3) NPs 5.63 - 42.21 ± 0.56 mV  Good stability 
Mag-SiO2-Ca(17)  NPs 6.23 - 21.74 ± 1.61 mV Incipient instability  
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Figure 24. Sedimentation test of magnetic nanoparticles without magnet. 
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Figure 25. Sedimentation test of magnetic nanoparticles with magnet. 
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3.3.8 Not direct contact cytotoxicity evaluation of second synthesis of MNPs 
 
Cell viability results were evaluated with MTT assay (Figures 26-27). The percentages of cell 
viability for not direct contact cytotoxicity evaluation of 24 h were in a range between 90% and 
95% for Mag NPs leaching solution (Fig. 26). Cell viability after contact with Mag-SiO2 NPs 
leaching solution (Fig. 26) was in a range between 92% and 97%. Moreover, the percentages of cell 
viability were in a range between 91% and 97% for Mag-SiO2-Ca(3) NPs leaching solution and 
between 87% and 93% for Mag-SiO2-Ca(17) NPs leaching solution respectively (Fig. 26).    
Not direct contact cytotoxicity evaluation of 72 h showed a cell viability in range between 88% and 
94% for Mag NPs leaching solution (Fig. 27). Cell viability after contact with Mag-SiO2 NPs 
leaching solution was in a range between 89% and 95% (Fig. 27). Moreover, cell viability after 
contact with Mag-SiO2-Ca(3) NPs leaching solution was in a range between 88% and 94% (Fig. 
27). Finally, cell viability after contact with Mag-SiO2-Ca(17) NPs leaching solution was in a range 
between 85% and 91% (Fig. 27). The results of cytotoxicity evaluation for not direct contact of 
culture medium DMEM with MNPs using ISO 10993 standards showed a cell viability comparable 
to control. Trypan blue assay validated the results obtained with MTT assay (Tables 10 and 11).  
Differences were statistically significant at 24, 48 and 72 h time-points (p < 0.05). 
 
 
 
52 
 
Figure 26. Not direct contact cytotoxicity evaluation of MNPs using murine endothelial cells (MS1 cells) 
and eluates (24 h of soaking); MTT assay. Data are shown as the mean ± standard deviation (n = 4). *P < 
0.05 compared with control.   
 
 
 
 
Not direct contact cytotoxicity (37°C for 24 h) - Percentage 
of TB positive MS1 cells 
Samples 24 h 48 h 72 h 
Mag 4.8 + 0.7 8.0 + 0.9 9.6 + 0.8* 
Mag-SiO2 3.2 + 0.4 5.5 + 0.5 8.9 + 1.0* 
Mag-SiO2-Ca(3) 3.9 + 0.5 6.8 + 0.7 7.8 + 0.7* 
Mag-SiO2-Ca(17) 6.5 + 0.6 9.7 + 0.8* 13.2 + 0.9* 
 
Table 10. Trypan blue exclusion test. MS1 cell mortality after not direct contact with MNPs (37°C for 24 h). 
Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
 
 
 
Figure 27. Not direct contact cytotoxicity evaluation of MNPs using murine endothelial cells (MS1 cells) 
and eluates (72 h of soaking). Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared 
with control. 
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Not direct contact cytotoxicity (37°C for 72 h) - Percentage 
of TB positive MS1 cells 
Samples 24 h 48 h 72 h 
Mag 6.1 + 0.7 8.7 + 0.8 11.8 + 0.8* 
Mag-SiO2 4.9 + 0.5 6.8 + 1.0 10.9 + 1.1* 
Mag-SiO2-Ca(3) 5.8 + 0.9 9.4 + 0.7 12.7 + 0.9* 
Mag-SiO2-Ca(17) 9.3 + 1.2 12.1 + 1.1* 15.2 + 1.0* 
 
Table 11. Trypan blue exclusion test. MS1 cell mortality after not direct contact with MNPs (37°C for 72 h). 
Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
 
3.3.9 Direct static contact cytotoxicity evaluation of second synthesis of MNPs 
 
In direct static contact cytotoxicity tests, MS1 endothelial cells showed a cell viability ranging 
between 80% and 97% for Mag NPs, 86% and 95% for Mag-SiO2 NPs, 59% and 85% for Mag-
SiO2-Ca(3) NPs, 45% and 82% for Mag-SiO2-Ca(17) NPs (Figures 28-30). Calcium-silica MNPs 
displayed a higher toxicity respect to calcium-free MNPs on MS1 cells. MS1 cells viability after 
contact with calcium-silica MNPs was dose-dependent and time-dependent. Moreover, the amount 
of Ca
2+
 ions incorporated in the nanoparticles could have played a role on the cytocompatibility of 
the MNPs, since at higher ratios a lower cell survival was observed (p < 0.05). Trypan blue assay 
validated the results obtained using MTT assay (Tables 12-14). Data were considered statistically 
significant (p < 0.05). No cellular morphological alterations were observed after direct contact with 
MNPs (Fig. 31-33). 
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Figure 28. Cytocompatibility assessment of MS1 cells after 24 hours in contact with different concentration 
of MNPs. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control 
samples. 
 
 
 
Percentage of TB positive MS1 cells after 24 hours of contact with MNPs 
Sample 10 μg/ml 20 μg/ml 40 μg/ml 
 
80 μg/ml 
Mag NPs 3.2 ± 0.5 4.6 ± 0.7 11.7 ± 0.8* 16.9 ± 0.9* 
Mag-SiO2 NPs  6.3 ± 0.8 8.4 ± 0.6 9.2 ± 0.6* 11.2 ± 1.0*
 
Mag-SiO2-Ca(3) NPs 13.5 ± 1.0* 15.0 ± 0.9* 22.1 ± 1.2* 28.8 ± 0.7* 
Mag-SiO2-Ca(17) NPs 15.8 ± 1.2* 17.8 ± 1.1* 24.4 ± 1.3* 31.3 ± 1.1* 
 
Table 12. Trypan blue exclusion test. MS1 cell mortality after contact of 24 hours with nanoparticles. Data 
are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control samples. 
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Figure 29. Cytocompatibility assessment of MS1 cells after 48 hours in contact with different concentration 
of MNPs. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. **P < 
0.05 compared with Mag-SiO2-Ca(3) and control samples. 
 
 
 
Percentage of TB positive MS1 cells after 48 hours of contact with MNPs 
Sample 10 μg/ml 20 μg/ml 40 μg/ml 
 
80 μg/ml 
Mag NPs 5.2 ± 0.6 7.4 ± 0.9 14.3 ± 1.2* 19.2 ± 0.7* 
Mag- SiO2 NPs  8.2 ± 0.9 12.2 ± 0.5* 12.8 ± 0.7* 15.3 ± 1.2* 
Mag-SiO2-Ca(3) NPs 16.5 ± 1.3* 24.3 ± 1.1* 29.3 ± 0.8* 33.1 ± 0.9* 
Mag-SiO2-Ca(17) NPs 19.7 ± 0.9* 31.8 ± 1.4* 38.4 ± 1.2* 42.8 ± 1.3* 
 
Table 13. Trypan blue exclusion test. MS1 cell mortality after contact of 48 hours with nanoparticles. Data 
are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control samples. 
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Figure 30. Cytocompatibility assessment of MS1 cells after 72 hours in contact with different concentration 
of MNPs. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control 
samples. **P < 0.05 compared with Mag-SiO2-Ca(3) and control samples. 
 
 
 
 
Percentage of TB positive MS1 cells after 72 hours of contact with MNPs 
Sample 10 μg/ml 20 μg/ml 40 μg/ml 
 
80 μg/ml 
Mag NPs 7.2 ± 0.9 9.2 ± 1.1 16.5 ± 0.6* 21.4 ± 0.8* 
Mag- SiO2 NPs  9.1 ± 0.7 14.2 ± 0.8* 17.2 ± 0.8* 17.4 ± 1.0* 
Mag-SiO2-Ca(3) NPs 20.4 ± 1.1* 35.4 ± 1.2* 38.1 ± 1.2* 41.6 ± 1.2* 
Mag-SiO2-Ca(17) NPs 24.2 ± 0.6* 50.7 ± 1.0* 54.2 ± 0.9* 55.8 ± 0.9* 
 
Table 14. Trypan blue exclusion test. MS1 cell mortality after contact of 72 hours with nanoparticles. Data 
are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control samples. 
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Figure 31. Optical microscopic images of endothelial cells (MS1 cells) after direct contact with MNPs (10-
80 µg/ml) for 24 hours. Magnification: 20x, bar scale = 50 µm. No effects are observed on cell 
morphological features.  
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Figure 32. Optical microscopic images of endothelial cells (MS1 cells) after direct contact with MNPs (10-
80 µg/ml) for 48 hours. Magnification: 20x, bar scale = 50 µm. No effects are observed on cell 
morphological features.  
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Figure 33. Optical microscopic images of endothelial cells (MS1 cells) after direct contact with MNPs (10-
80 µg/ml) for 72 hours. Magnification: 20x, bar scale = 50 µm. No effects are observed on cell 
morphological features.  
 
 
3.3.10 Lactate dehydrogenase assay 
 
The lactate dehydrogenase assay is a convenient method for evaluation of cell damage, as indicated 
by lactate dehydrogenase release from the cytosol of lysed cells. LDH leakage from MNPs reflects 
cell membrane disruption. The lactate dehydrogenase results on MS1 cells were consistent with 
those of the MTT assay (Figures 34-36). All types of MNPs stimulated LDH release in a 
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concentration-dependent manner. LDH release of Mag NPs and Mag-SiO2 NPs (in a range between 
3.09 and 5.13%) was lower than calcium-silica core-shell type iron oxide nanoparticles (in a range 
between 4.69 and 8.87%) after 24, 48 and 72 hours, suggesting less cell membrane damage. Data 
were considered statistically significant (p < 0.05). 
 
 
 
 
Figure 34. Effect of MNPs on cell-membrane integrity following exposure to increasing concentrations of 
MNPs for 24 hours. The relative lactate dehydrogenase (LDH) release was co-related to percentage 
cytotoxicity. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
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Figure 35. Effect of MNPs on cell-membrane integrity following exposure to increasing concentrations of 
MNPs for 48 hours. The relative lactate dehydrogenase (LDH) release was co-related to percentage 
cytotoxicity. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
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Figure 36. Effect of MNPs on cell-membrane integrity following exposure to increasing concentrations of 
MNPs for 72 hours. The relative lactate dehydrogenase (LDH) release was co-related to percentage 
cytotoxicity. Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
 
 
 
3.3.11 Cells morphology evaluation by fluorescent microscopy 
No cellular morphological alterations were observed between cells in direct contact with MNPs and 
control using IF staining (Figures 37-39). These results confirmed that MNPs had not adverse 
effects on the cytoskeleton and cell morphology. Some problem of MNPs cytotoxicity could be 
related to their accumulation in tissues and organs. Afterwards this aspect will be investigated in 
next chapter by using a bioreactor with microfluidic technology and by in vivo biodistribution of 
MNPs.  
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Figure 37. IF staining with DAPI (blue) and phalloidin (red) of cells seeded for 24 h in contact with 
nanoparticles: Mag, Mag-SiO2, Mag-SiO2-Ca(3), Mag-SiO2-Ca(17) and control. Magnification: 20x, bar 
scale = 50 µm. 
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Figure 38. IF staining with DAPI (blue) and phalloidin (red) of cells seeded for 48 h in contact with 
nanoparticles: Mag, Mag-SiO2, Mag-SiO2-Ca(3), Mag-SiO2-Ca(17) and control. Magnification: 20x, bar 
scale = 50 µm. 
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Figure 39. IF staining with DAPI (blue) and phalloidin (red) of cells seeded for 72 h in contact with 
nanoparticles: Mag, Mag-SiO2, Mag-SiO2-Ca(3), Mag-SiO2-Ca(17) and control. Magnification: 20x, bar 
scale = 50 µm. 
 
 
3.4 Discussion 
 
Spherical MNPs were synthesized, with a diameter around 10-15 nm. MNPs consisting of 
magnetite or a core of magnetite coated with silica or calcium-silica were obtained. The addition of 
citric acid during the synthesis process increased their dispersibility and colloidal stability compared 
to the first synthesis of MNPs. Moreover, a second synthesis of MNPs was produced to improve 
their cytocompatibility compared to first synthesis. Ca
2+
 ions were introduced in order to enhance 
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MNPs surface reactivity for future functionalization with different moieties. Zeta potential was 
measured to determine the degree of the electrostatic or charge repulsion or attraction between 
nanoparticles, and is one of the fundamental parameters known to affect stability. In addition, it is 
useful to determine the best coating to be used to enhance the properties of the surface charge of the 
nanoparticles. Zeta potential of magnetic nanoparticles was measured to different acid and basic pH 
values in order to evaluate the overall trend of colloidal properties by varying the isoelectric point 
of the solution that contains the nanoparticles. Zeta potential measurements revealed a greater 
colloidal stability behavior of second synthesis of MNPs compared to the first synthesis. 
The magnetic characterization of second synthesis of MNPs by using vibrating sample 
magnetometer (VSM-Lakeshore) to measure magnetic hysteresis showed that all types of MNPs 
have superparamagnetic properties. AFM/MFM observation of MNPs was useful to investigate 
magnetic forces, but also atomic and electrostatic forces.  
Cell viability evaluation demonstrated that Mag NPs and Mag-SiO2 NPs are cytocompatible and 
comparable to the control till the concentration of 80 µg/ml. The NP surface is crucial to improve 
dispersibility and biocompatibility of MNPs.   
On the contrary Mag-SiO2-Ca(3) NPs and Mag-SiO2-Ca(17) were not cytocompatible. A possible 
explanation of the cytotoxicity effect observed could be the transient absorption of Ca
2+
 ions on the 
amorphous shell and their subsequent release of Ca
2+
 ions in cell culture medium, which are toxic to 
the cells. In fact, NPs with a higher ratio of Ca
2+
 ions displayed a higher level of toxicity compared 
to low Si:Ca ratio (p < 0.05). Finally to further improve the dispersibility and separation of MNPs, 
the implementation of ultrafiltration techniques will be achieved in the next chapter. The future goal 
is to realize functionalized magnetic nanoparticles which minimize not direct and direct toxic 
effects and improve assembling of MNPs with drugs, chemicals and antibodies.   
 
3.5 Conclusion 
 
This new synthesis of MNPs showed a considerable improvement of colloidal properties of 
nanoparticles using citric acid like dispersant respect to first synthesis. Mag and Mag-SiO2 NPs 
prepared with the addition of citric acid showed cytocompatibility comparable to control in both 
direct and not direct conditions. In addition the new formulation for the preparation of Mag and 
Mag-SiO2 NPs in the second synthesis improved their cytocompatibility in not direct conditions  
respect to the first synthesis. However the new nanoparticles with calcium synthesized in the second 
synthesis did not show cytocompatibility comparable to control, probably due to the release of Ca
2+
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ions from MNPs in cell culture media which affected cell viability of MS1 cells. In fact in the next 
chapter this aspect will be addressed by preparing calcium-silica iron-oxide nanoparticles with a 
more efficient synthesis procedure. 
 
Chapter 4 
 
In vitro and in vivo biological characterization of magnetic nanoparticles 
obtained via co-precipitation methods using citric acid as dispersant 
  
4.1 Aim 
The third synthesis of magnetic nanoparticles was optimized to reach the best physical-chemical 
properties and evaluate the biocompatibility of the nanoparticles in different conditions. MNPs of 
third synthesis were assessed for their cytocompatibility using various approaches including 
leaching tests, static and dynamic direct contact tests. In fact naked Fe3O4 nanoparticles (Mag) were 
compared with those covered by silica shell (Mag-SiO2) in static and dynamic conditions of 
cytocompatibility. Two concentrations of MNPs: 2 and 20 µg/ml were standardized for 
cytocompatibility tests to avoid problems of cytotoxicity related to high concentrations of MNPs, as 
observed in the previous chapters. In addition, the characterization of magnetic nanoparticles was 
extended analyzing the aspects of in vivo biocompatibility of MNPs. Dynamic cell in vitro 
evaluation was implemented to minimize the MNPs cluster effect on cytocompatibility of MS1 
cells. Noteworthy is the fact that the static cytotoxicity may, however, be more pronounced in vitro 
than in vivo because in cell culture conditions the NPs and/or their degradation products (which can 
affect cell viability) remain in close contact with the cells and may act as a depot showing 
continuous effect. For this reason, we implemented a cytotoxicity test of MNPs in dynamic 
conditions. On the contrary, NPs are in vivo continuously eliminated from the body when they are 
biodegradable, as reported in literature [54]. Thus, it is obvious that the assessment of in vivo safety 
of MNPs is essential for any type of application.  
The investigation of third synthesis of MNPs was aimed to evaluate systemic biodistribution, after 
intravenous injection, of magnetic nanoparticles with and without silica coating. Only Mag and 
Mag-SiO2 NPs were tested for in vivo biodistribution because in vitro cell viability tests showed 
that they were more cytocompatible in comparison with calcium-silica core-shell type MNPs, as 
described in the previous chapter. A further synthesis of MNPs was prepared for two reasons: 1) the 
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previous synthesis of MNPs had a low yield production and 2) calcium-silica core-shell type MNPs 
showed problems of cytotoxicity on murine endothelial cells. Thus, yield production of third 
synthesis of MNPs was improved by separating and washing MNPs extensively with water using an 
ultrafiltration device. Moreover, it was investigated the reason of cytotoxicity observed for calcium-
silica MNPs in the previous synthesis if it’s due to the Ca2+ precursor used for their production. To 
solve this problem two different Ca
2+
 precursors (calcium citrate and calcium hydroxide) were 
compared. In this way it was possible to compare the precursor (calcium citrate) used in the second 
synthesis of MNPs respect to the final preparation of MNPs.  
 
4.2 Materials and methods 
4.2.1 Nanoparticles preparation   
Four different types of magnetic nanoparticles (MNPs) were studied: Mag, Mag-SiO2, Mag-SiO2-
Ca(3) IDR, Mag-SiO2-Ca(3) CITR. In the third synthesis a different method of preparation of 
calcium-silica MNPs with Si:Ca ratio 99:1 (MSC(3)) was implemented by using two different Ca
2+
 
precursors: calcium citrate and calcium hydroxide. These nanoparticles were produced by 
Politecnico di Torino in the laboratory of the Applied Science and Technology Department directed 
by Prof. Enrica Vernè. The preliminary physico-chemical characterization of the nanoparticles was 
performed by Politecnico di Torino as following reported. Their main characteristics are described 
in Table 15. Three of them consisted of a magnetite core covered by an amorphous silica shell 
(Mag-SiO2) (Figure 40). 
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Figure 40. Schematic representation of silica core-shell type magnetic nanoparticles. 
SAMPLE MATERIAL MEDIUM Concentration 
of MNPs 
stock solution  
pH 
approx 
Notes 
Mag Citric acid treated magnetite 
nanoparticles 
Water 1.8 mg/ml 9.6 Stable in 
solution 
for weeks 
Mag-SiO2 SiO2 coated citric acid 
stabilized magnetite 
nanoparticles 
Water 3.4 mg/ml 7.9 Stable in 
solution 
for weeks 
Mag-SiO2-
Ca(3) IDR 
SiO2 – Ca (low amount Ca) 
coated citric acid stabilized 
magnetite nanoparticles 
produced from the precursor: 
calcium hydroxide 
Water 4.4 mg/ml 9.2 Stable in 
solution 
for weeks 
Mag-SiO2-
Ca(3) 
SiO2 - Ca (low amount Ca) 
coated citric acid stabilized 
Water 4.5 mg/ml 8.3 Stable in 
solution 
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CITR magnetite nanoparticles 
produced from the precursor: 
calcium citrate 
for weeks 
 
Table 15. Main characteristics of MNPs synthesized via co-precipitation methods using citric acid. 
 
4.2.2 Nanoparticles: synthesis of MNPs 
 
Magnetite nanoparticles (Mag) were produced by co-precipitation method [101] as explained in 
chapter 2.2.1. Aqueous solutions of FeCl2 and FeCl3 were mixed and pH was brought to basic 
values (about 10.0) by dropwise NH4OH addition.  
To improve water dispensability of the MNPs, a treatment of magnetite with citric acid was carried 
out by soaking nanoparticles in citric acid solution (0.05 M) for 3 h and then exhaustively washed 
with water.   
At the end of nanoparticles synthesis and fictionalization with citric acid, by adding tetraethyl 
orthosilicate (TEOS) (a silica precursor), with ethanol and water as solvent, an amorphous silica 
shell (Mag-SiO2) was obtained.  
To avoid the uncontrolled TEOS polymerization in the reaction media and to optimize the silica 
shell [107], the TEOS amount was reduced and concomitantly ethanol was added in the synthesis 
step, as described in the Stöber method [102]. The nanoparticles were then separated and washed 
extensively with water using an ultrafiltration device. 
To obtain calcium-silica magnetite NPs, calcium citrate and calcium hydroxide were selected as 
precursors of Ca
2+
 ions and thus added in the synthesis process together with TEOS to reach 99:1 
(Mag-SiO2-Ca(3) CITR and IDR) Si:Ca ratio. 
 
4.2.3 Nanoparticles characterization  
As previously described in the paragraph 3.2.3.  
 
4.2.4 Magnetic performance testing 
 
As previously described in the paragraph 3.2.5.  
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4.2.5 Zeta potential 
 
As previously described in the paragraph 3.2.8.  
 
4.2.6 Cell culture 
As previously described in the paragraph 2.2.2. 
 
4.2.7 Cell viability evaluation using MTT assay 
As previously described in the paragraph 2.2.3.  
 
 
4.2.8 Not direct contact cytotoxicity evaluation of MNPs 
 
As previously described in the paragraph 2.2.3.  
 
4.2.9 Direct contact cytotoxicity evaluation of MNPs in static conditions 
Mag, Mag-SiO2, Mag-SiO2-Ca(3) CITR and Mag-SiO2-Ca(3) IDR nanoparticles were tested for 
cytocompatibility in static conditions. Direct contact static cytotoxicity evaluation was done 
according to ISO standard 10993-5: 2009. The cells were seeded in 24-well plates (1,6 x 10
4
 cells 
per well) in DMEM medium and cultured for 24 h at 37°C in 5% CO2 atmosphere-controlled 
incubator. After 24 hours the medium was substituted with a new one obtained by adding MNPs to 
DMEM to obtain the following concentrations: 2 μg/ml, 20 μg/ml (w/v). Media without MNPs were 
used as comparison. Cells viability of MS1 cells was evaluated using MTT assay after 24, 48 and 
72 h. Furthermore, cells morphology for direct contact cytotoxicity evaluation in static conditions 
was visually investigated at each experimental time by light microscopy (Leica AF 6500, Leica 
Microsystems) at 20x magnification.  
 
 
4.2.10 Cells morphology evaluation by fluorescent microscopy 
 
As previously described in the paragraph 3.2.13.  
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4.2.11 Reactive oxygen species (ROS) in cells 
 
The production of ROS in cells was measured using CellROX Oxidative Stress Reagents (Life 
Technologies) as an oxidation-sensitive probe. CellROX Oxidative Stress Reagents are fluorogenic 
probes designed to reliably measure reactive oxygen species (ROS) in live cells. CellROX Green 
Reagent is a DNA dye, and upon oxidation, it binds to DNA; thus, its signal is localized primarily 
in the nucleus and mitochondria. Briefly, 2.5 mM CellROX Green Reagent stock solution was 
diluted 500-fold with cell culture medium without serum or other additives to prepare a 5 µM 
working solution. MS1 cells were seeded in 12-well plates (7.5 x 10
4
 cells per well). After exposure 
to Mag, Mag-SiO2, Mag-SiO2-Ca(3) CITR and Mag-SiO2-Ca(3) IDR NPs at the concentrations of 2 
and 20 µg/ml for 24 h, the cells were washed with PBS and incubated in 1 mL of CellROX Green 
Reagent at a final concentration of 5 μM at 37°C in the dark for 30 min. Experimental time-point 
(24 h) of ROS production induced by MNPs was chosen according to literature [103, 104]. 
Menadione (25 µM) was used as a positive control. Then, MS1 cells were analyzed with Flow 
cytometry at an excitation wavelength of 485 nm for CellROX Green Reagent. Statistical data were 
obtained from the dot plots using CellQuest software (BD Biosciences). 
 
4.2.12 Apoptosis evaluation 
MS1 cells were seeded at a density of 2,5 × 10
5
 cells for 24 hours and 1,75 × 10
5
 cells for 48 and 72 
hours on Petri dishes, then treated with Mag and Mag-SiO2 NPs at different concentrations (2 and 
20 µg/ml in DMEM respectively) at 37 °C. Following incubation for 24, 48 and 72 h, Annexin V-
FITC and PI double staining was performed according to the manufacturer’s instructions. Cells 
were collected by centrifugation, washed twice with cold PBS, and a cell  suspension was prepared 
by  adding 400 µl x 1 binding buffer and 10 µl Annexin V-FITC, which was incubated for 15 min at 
4 °C in the dark. Finally, 10 µl PI was added and incubated for 15 min under the same conditions. 
Flow cytometry experiments were carried out at an excitation wavelength of 488 nm for Annexin 
V-FITC and PI. The obtained data from the dot plots using CellQuest software (BD Biosciences) 
were analyzed by means of frequency distribution table and descriptive statistics using IBM SPSS 
(version 20) and Chi-square test. 
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4.2.13 Direct contact cytotoxicity evaluation of MNPs in dynamic conditions 
Experiments were repeated in dynamic conditions using a continuous flow bioreactor (Figure 41) 
with a peristaltic pump simulating the blood stream in a capillary. MS1 cells were seeded at 
confluence on a strip (2.4 cm x 0.6 cm) of polycaprolactone (PCL) supports (30.000 cells/cm
2
). 
When MS1 cells were confluent, the strips were inserted in the bioreactor and the cells were 
subjected to a continuous flow of cell culture medium (DMEM) with MNPs at the concentration of 
20 µg/ml. Experiments were carried out in humidified incubator at 37°C, 5% CO2 atmosphere and 
stopped at the following experimental times: 2 h, 12 h and 24 h. Cell viability was then evaluated 
using LDH assay and XTT assay. Moreover, cell morphology was analyzed with FESEM equipped 
to EDS probe, in order to evaluate the presence, if any, of Mag and Mag-SiO2 nanoparticles 
deposits.  
 
Figure 41. a) Microfluidics bioreactor used for cytocompatibility evaluation of MNPs in dynamic 
conditions, b) Peristaltic pump of bioreactor, c) Perfusion chamber of bioreactor disassembled, d) Perfusion 
chamber of bioreactor assembled. Bioreactor was kindly set up and provided by Prof. Silvia Farè - 
Politecnico di Milano. 
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4.2.14 Lactate dehydrogenase assay 
The possible adverse effects of MNPs on MS1 cells subjected to a continuous flow in a bioreactor 
were assayed using a LDH Cytotoxicity Assay Kit (Gesan group). The assay was performed as per 
the manufacturer’s instructions. LDH is released by cells in response to damage or loss of integrity 
of cell membrane and is a cellular toxicity indicator. Briefly, MS1 cells were seeded at confluence 
on a strip of polycaprolactone (PCL) and subjected to a continuous flow of cell culture medium 
(DMEM) with MNPs at concentration of 20 µg/ml for three experimental times: 2, 12 and 24 h. 
Untreated cells were taken as the negative control and cells treated with lysis buffer were taken as 
the high control (total LDH in the cell). As a positive control, 1 μL of LDH was used to validate the 
assay. Following the incubation with NPs, the well plates were centrifuged at 600 g for 10 minutes 
and 10 μL of the medium was transferred to a fresh 96-well plate. The medium was then incubated 
with 100 μL of LDH reaction mixture for 15 minutes at room temperature and the absorbance was 
measured at 450 nm using the microplate reader (Victor X4 - PerkinElmer) with the reference 
wavelength at 650 nm. LDH was quantified using the following formula:  
LDH% =        Test – low control          x 100 
                High control – low control 
in which “low control” was the cells without any treatment and “high control” was the cells treated 
with lysis buffer (total LDH). 
 
4.2.15 XTT assay 
The 2,3-bis (2-methoxy-4-nitro-5-sulphophenyl)-5-[(phenyl amino) carbonyl]-2H-tetrazolium 
hydroxide (XTT; Sigma) colorimetric assay was used to determine mitochondrial dehydrogenase 
activity as an indicator of the metabolic state of MS1 cells seeded at confluence on a strip of 
polycaprolactone (PCL) and subjected to a continuous flow of cell culture medium (DMEM) with 
MNPs at concentration of 20 µg/ml for three experimental times: 2, 12 and 24 h. 50 µL XTT 
solution (1 mg/mL in PBS) and 4 µL menadione solution (1 mM in acetone) were used for each 
strip. Plates were incubated for 5 hours in the dark at 37°C. After the supernatant was centrifuged 
into new 1-mL Eppendorf tubes and centrifuged (5 min, 13,000 rpm) to remove residual cells. From 
each tube, 200 µL was transferred to a new 96-well plate and XTT formazan [OD] (optical density) 
in the supernatant was determined spectrophotometrically at 690 nm.   
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4.2.16 Biodistribution of MNPs 
Biocompatibility and biodistribution of the MNPs were studied after 7 days of administration in 
mice. The same concentrations of MNPs of in vitro experiments were tested for biodistribution in 
vivo. Mag and Mag-SiO2 nanoparticles were tested in vivo in mice using the following 
concentrations: 2 and 20 mg/kg body weight. In this way it was possible to investigate the dose-
dependent toxic effects induced in vivo by the magnetic nanoparticles. 
 
4.2.17 Animal experiments 
C57BL6 wild-type mice (8-10 weeks old with body weight of 20-25 g - purchased form Harlan) 
were treated according to protocols evaluated and approved by the Ethical Committee of University 
of Piemonte Orientale, Novara and to the National and European laws. 
Two doses of 2 and 20 mg/kg of Mag and Mag-SiO2 NPs were separately given to the mice via tail 
vein injections. 7 days post-injection, the mice were anesthetized with i.p. injection of an aqueous 
solution of 6 % chloral hydrate (6 ml/kg). Control experiments were carried out by injecting 
physiological saline solution (NaCl 0.9%). Four mice (2 males and 2 females) were used for each 
sample: Mag NPs, Mag-SiO2 NPs and control. Twelve mice were used for each dose of MNPs.  
 
4.2.18 Serum biochemical analysis 
The mice were intravenously administrated MNPs with a dose of 2 and 20 mg/kg. At 7 days post-
injection, 1 ml of blood was collected by removal through the eyeball before perfusion. Blood 
samples were allowed to clot at room temperature and centrifuged at 3,000 g for 10 min to separate 
the serum. The serum biochemical analysis were carried using a commercial kit according to the 
manufacturer’s instruction (LDH kit assay, Gesan Production). Aspartate transaminase (AST), 
alanine transaminase (ALT), creatinine (CRE), lactic acid dehydrogenase (LDH) were measured. 
Saline was used as a control. 
4.2.19 Hematological analysis 
Hematological parameters: red blood cell (RBC) and white blood cell (WBC) were measured using 
trypan blue staining for counting of blood cells. The blood was collected from mice by removal 
through the eyeball after 3 and 7 days. The cell counting was performed using a hemocytometer. 
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Because the high density of blood cells to allow cell counting, a diluition 1:200 blood:isotonic 
solution was performed. Once the blood sample was diluted, trypan blue was added on a 1:1 
proportion. Afterwards the blood cell counting was performed by hemocytometer according to 
literature [110]. The final number of RBC and WBC was calculated multiplying by 200 due to the 
initial dilution made, and additionally by 2 because of the viability dye. Cell counting was repeated 
three times. 
 
4.2.20 Organs explant 
 
The major organs (liver, spleen, brain, kidney, lung, and heart) were collected and analyzed from 
three points of view: 1) Macroscopic evaluation (organ weights); 2) Spectrometry evaluation for 
iron accumulation (Inductively coupled plasma-atomic emission spectrometry (ICP-AES)); 3) 
Histological evaluation of iron accumulation (Perls’ Prussian blue staining). 
After dissection organs were collected (from 4 mice for each MNP sample and control). The organs 
from three mice (per sample) were used for ICP-AES compositional evaluation, while organs from 
one mouse (per sample) were used for histological evaluation. For analysis in liver, only right lobes 
were used. 
 
4.2.21 Inductively coupled plasma-atomic emission spectrometry (ICP-AES) 
 
Inductively coupled plasma atomic emission spectroscopy (ICP-AES) is a very diffused analytical 
technique used for the detection of trace metals. It is a type of emission spectroscopy that uses the 
inductively coupled plasma to produce excited atoms and ions that emit electromagnetic radiation at 
wavelengths characteristic of a particular element [111, 112]. The intensity of this emission is 
indicative of the concentration of the element within the sample. The organs were digested 
overnight in an Erlenmeyer flask containing 8.0 ml of HNO3 (68 %) and 2.0 ml of HClO4 (70 %) at 
room temperature. Next, the digested sample was placed at 70 °C for 2 h, and then heated at 150 °C 
to remove the remaining acid. Finally, the remaining residue was dissolved in 1.0 ml of HNO3 and 
made up to the final volume of 500 ml for the iron quantification using ICP-AES. The amount of 
iron and silicon present in the organs was measured using ICP-AES. 
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4.2.22 Histological evaluation of iron accumulation   
 
The Perls’ Prussian blue staining was performed to control the presence and the intracellular 
accumulation of iron ions in tissues and organs of mice injected with magnetic nanoparticles. The 
underlying principle of the staining is the formation of a bright blue pigment called Prussian blue 
due to chemical interaction of ferrous or ferric ions present in the tissue sections with ferrocyanide. 
In brief paraffin-embedded tissue sections were fixed for 30 minutes in 4% paraformaldehyde. To 
reveal the presence of ferrous ions (Fe
2+
) paraffin-embedded tissue were pre-incubated for 20 
minutes with ammonium sulphide solution. The tissue sections were then washed with phosphate-
buffered solution and incubated with potassium hexacyanoferrate solution (2% potassium 
ferrocyanide/2% HCl, 1:1 v/v, Sigma, St Louis, MO) for 30 minutes to reveal ferric ions (Fe
3+
). 
Instead the sections incubated with potassium hexacyanoferrate solution (5% potassium 
ferrocyanide/1% HCl, 1:1 v/v, Sigma, St Louis, MO) for 30 minutes to verify the presence of 
ferrous ions. Finally, the tissue sections were counterstained with Nuclear Fast Red solution 
(Sigma-Aldrich), and observed under an inverted optical microscope. 
 
4.2.23 Statistical analyses 
All statistical analyses were performed using IBM Statistical Package for Social Sciences v. 20 
software (SPSS - IBM). Data were expressed as means ± standard deviations. The results were 
analyzed using one way analysis of variance (ANOVA) followed by Scheffe’s test, and P values 
less than 0.05 were considered to be statistically significant. 
 
4.3 Results 
4.3.1 MNPs diffraction signals  
Diffraction patterns of Mag, Mag-SiO2, Mag-SiO2-Ca(3) CITR and IDR NPs match the ones 
reported for magnetite [101] (Figure 42). The numbers in SAED patterns of MNPs refer to the 
distances of crystal planes of Mag, Mag-SiO2, Mag-SiO2-Ca(3) CITR and IDR NPs according to a 
defined crystallographic direction. In the case of Mag-SiO2 and Mag-SiO2-Ca(3) CITR and IDR 
samples broad halos can be observed together with the diffraction signals characteristics of 
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magnetite (that resulted a little attenuated), and can be attributed to the amorphous coating (Figure 
42).   
 
 
Figure 42. Diffraction signals of Mag NPs (a); Mag-SiO2 NPs (b); and Mag-SiO2-Ca(3) CITR and IDR NPs 
(c). .The numbers in SAED patterns refer to the distances of crystal planes of Mag and Mag-SiO2 NPs 
according to a defined crystallographic direction. 
 
4.3.2 Morphological observations 
TEM showed that the electron density of the magnetic nanoparticles was relatively high, and that 
the nanoparticles, which were spherical and partially agglomerated, had a primary diameter of 15 
nm and a shell (silica) with a thickness of 1-2 nm. Nanometric spherical particles (10-15 nm) with 
calcium and with a good dispersion in water were obtained. An effective enrichment in Ca
2+
 was 
verified for both formulations with an increased calcium content, according to expectancies (Figure 
45-46). EDS analysis confirmed the composition of the nanoparticles through a rough estimate 
(Figures 43-46). 
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Figure 43. TEM image and EDS spectrum of Mag nanoparticles. 
 
Figure 44. TEM image and EDS spectrum of Mag-SiO2 NPs. 
 
Figure 45. TEM image and EDS spectrum of Mag-SiO2-Ca(3) CITR NPs. 
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Figure 46. TEM image and EDS spectrum of Mag-SiO2-Ca(3) IDR NPs. 
 
 
4.3.3 Magnetic performance 
A vibrating sample magnetometer was used to measure the magnetic hysteresis of the magnetic 
nanoparticles at 300 K in an applied field of ± 15000 g. The results showed that the saturated 
magnetic intensity of Mag NPs was ± 40.5 emu/g. Instead, the saturated magnetic intensities were ± 
3.5 emu/g and ± 4.3 emu/g for Mag-SiO2 NPs and Mag-SiO2-Ca(3) CITR and IDR NPs 
respectively (Figure 47). The three lines of the hysteresis loop overlapped, ie, no coercivity was 
noted, indicating that the magnetic nanoparticles prepared were superparamagnetic. 
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Figure 47. Measurement of the magnetic hysteresis of Mag, Mag-SiO2, Mag-SiO2-Ca(3) CITR and IDR NPs 
- Magnetic performance.  
 
 
4.3.4 Zeta potential evaluation of third synthesis of MNPs 
 
Zeta-potential measurement is considered as a key parameter for providing an insight into the 
colloidal stability of the resulting magnetic nanoparticles. The zeta-potential results are shown in 
Fig. 48. The zeta potential of suspension for Mag NPs, Mag-SiO2 NPs, Mag-SiO2-Ca(3) CITR and 
IDR NPs is - 30.23 mV, - 29.41 mV, - 43.14 mV respectively (Table 16). Zeta potential 
measurements revealed an incipient colloidal instability for Mag-SiO2 NPs, a moderate colloidal 
stability for Mag NPs and a good colloidal stability for Mag-SiO2-Ca(3) CITR and IDR NPs. 
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Figure 48. Zeta Potential measurements of third synthesis of MNPs. Data are shown as the mean ± standard 
deviation (n = 3). The black circles indicate starting pH of the solutions with MNPs. 
 
 
 
Table 16. Zeta Potential measurements of third synthesis of MNPs. Data are shown as the mean ± standard 
deviation (n = 3). 
 
 
4.3.5 Not direct contact cytotoxicity evaluation of third synthesis of MNPs 
 
Cell viability was evaluated with MTT assay (Figures 49-50). The percentages of cell viability for 
not direct contact cytotoxicity evaluation after 24 h were in a range between 91% and 94% for Mag 
NPs leaching solution (Fig. 49). Cell viability after contact with Mag-SiO2 NPs leaching solution 
was in a range between 92% and 96% (Fig. 49). Moreover, the percentages of cell viability were  in 
Sample Starting 
pH  
ZP (mV) Stability behaviour of the 
colloid  
Mag NPs 4.26 - 30.23 ± 1.49 mV  Moderate stability 
Mag-SiO2 NPs 4.70 - 29.41 ± 0.81 mV  Incipient instability 
Mag-SiO2-Ca(3) CITR and IDR 
NPs 
5.63 - 43.14 ± 1.95 mV  Good stability 
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a range between 89% and 93% for Mag-SiO2-Ca(3) IDR NPs leaching solution and between 88% 
and 94% for Mag-SiO2-Ca(3) CITR NPs leaching solution respectively (Fig. 49).   
Not direct contact cytotoxicity evaluation after 72 h showed a cell viability in range between 89% 
and 93% for Mag NPs leaching solution (Fig. 50). Cell viability after contact with Mag-SiO2 NPs 
leaching solution (Fig. 50) was in a range between 90% and 95%. Moreover, cell viability after 
contact with Mag-SiO2-Ca(3) IDR NPs leaching solution (Fig. 50) was in a range between 87% and 
93%. Finally, cell viability after contact with Mag-SiO2-Ca(3) CITR NPs leaching solution (Fig. 
50) was in a range between 86% and 92%. The results of cytotoxicity evaluation for not direct 
contact of culture medium DMEM with MNPs using ISO 10993 standards showed a cell viability 
comparable to control. Trypan blue assay validated the results obtained with MTT assay (Tables 17 
and 18). Differences were statistically significant at 24, 48 and 72 h time-points (p < 0.05). 
 
 
Figure 49. Not direct contact cytotoxicity evaluation of MNPs using murine endothelial cells (MS1 cells) 
and eluates (24 h of soaking); MTT assay. Data are shown as the mean ± standard deviation (n = 4). 
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Not direct contact cytotoxicity (37°C for 24 h) - Percentage of TB 
positive MS1 cells  
Samples 24 h 48 h 72 h 
Mag NPs 6.4 + 0.5 7.3 + 0.8 9.0 + 0.8 
Mag-SiO2  NPs  3.8 + 0.7 5.7 + 0.5 7.8 + 0.6 
Mag-SiO2-Ca(3) IDR NPs 6.9 + 0.8 8.6 + 0.9 10.5 + 0.9* 
Mag-SiO2-Ca(3) CITR NPs 5.5 + 0.6 7.7 + 0.7 11.7 + 1.0* 
 
 
Table 17. Trypan blue exclusion test. MS1 cell mortality after not direct contact with MNPs (37°C for 24 h). 
Data are shown as the mean ± standard deviation (n = 4).*P < 0.05 compared with control. 
 
 
Figure 50. Not direct contact cytotoxicity evaluation of MNPs using murine endothelial cells (MS1 cells) 
and eluates (72 h of soaking); MTT assay. Data are shown as the mean ± standard deviation (n = 4). 
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Not direct contact cytotoxicity (37°C for 72 h) - Percentage of TB 
positive MS1 cells 
Samples 24 h 48 h 72 h 
Mag NPs 6.8 + 0.5 8.7 + 1.0 10.5 + 0.8* 
Mag-SiO2  NPs  4.3 + 0.4 6.5 + 0.7 9.3 + 0.6 
Mag-SiO2-Ca(3) IDR NPs 6.7 + 0.7 10.4 + 0.8* 12.7 + 1.1* 
Mag-SiO2-Ca(3) CITR NPs 7.5 + 0.6 9.8 + 0.9 13.6 + 0.7* 
 
 
Table 18. Trypan blue exclusion test. MS1 cell mortality after not direct contact with MNPs (37°C for 72 h). 
Data are shown as the mean ± standard deviation (n = 4).*P < 0.05 compared with control. 
 
 
4.3.6 Direct static contact cytotoxicity 
Two different concentrations of MNPs (2 and 20 µg/ml) were used in direct static cytotoxicity tests. 
After 24 hours, using a concentration of 2 µg/ml of MNPs it was not observed a reduction of cell 
viability for all MNPs (Fig. 51). Afterwards also raising 10-fold the concentration of nanoparticles 
tested (20 µg/ml) their cytotoxicity did not increase so much but only in a percentage ranging 
between 4% and 9%. The same trend of cell viability (MS1 cells) was observed after 48 and 72 
hours of static direct contact for all nanoparticles (Fig. 52 and 53). Mag-SiO2 nanoparticles (84-
95%) showed the endothelial cell viability not significantly different compared to Mag 
nanoparticles (89-98%). Cell viabilities slightly decreased for Mag-SiO2-Ca(3) IDR and Mag -SiO2-
Ca(3) CITR nanoparticles but these reductions of cell viability were generally modest (Fig. 52 and 
53). Trypan blue assay validated the results obtained with MTT assay (Tables 19-21). In general 
these data of cell viability reassure on the cytocompatibility of these nanoparticles in static 
conditions comparable to the control. No morphological alterations were observed between cells in 
direct contact with MNPs and control using microscopic observation (Fig. 54-56). 
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Figure 51. Cytocompatibility assessment of MS1 cells after 24 hours in contact with two concentrations of 
MNPs (2 and 20 µg/ml). Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with 
control. 
 
 
 
Percentage of TB positive MS1 cells after 24 hours of 
contact with MNPs 
Sample 2 μg/ml 20 μg/ml 
Mag NPs 2.1 ± 0.5 6.2 ± 0.7 
Mag-SiO2  NPs  5.2 ± 0.8 8.9 ± 0.6 
Mag-SiO2-Ca(3) IDR NPs 7.8 ± 1.0 15.3 ± 0.9* 
Mag-SiO2-Ca(3) CITR NPs 7.1 ± 0.7 16.0 ± 1.0* 
 
 
Table 19. Trypan blue exclusion test. MS1 cell mortality after direct contact of 24 hours with nanoparticles. 
Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
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Figure 52. Cytocompatibility assessment of MS1 cells after 48 hours in contact with two concentrations of 
MNPs (2 and 20 µg/ml). Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with 
control. 
 
 
 
 
 
Percentage of TB positive MS1 cells after 48 hours of 
contact with MNPs 
Sample 2 μg/ml 20 μg/ml 
Mag NPs 4.2 ± 0.6 9.1 ± 0.5 
Mag-SiO2  NPs  8.1 ± 0.7 13.3 ± 0.7* 
Mag-SiO2-Ca(3) IDR NPs 12.2 ± 0.9* 17.9 ± 0.6* 
Mag-SiO2-Ca(3) CITR NPs 13.1 ± 0.8* 19.2 ± 1.0* 
 
 
Table 20. Trypan blue exclusion test. MS1 cell mortality after direct contact of 48 hours with nanoparticles. 
Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
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Figure 53. Cytocompatibility assessment of MS1 cells after 72 hours in contact with two concentrations of 
MNPs (2 and 20 µg/ml). Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with 
control. 
 
 
 
Percentage of TB positive MS1 cells after 72 hours of 
contact with MNPs 
Sample 2 μg/ml 20 μg/ml 
Mag NPs 6.3 ± 0.8 10.9 ± 0.9* 
Mag-SiO2  NPs  12.1 ± 0.6* 15.6 ± 0.8* 
Mag-SiO2-Ca(3) IDR NPs 14.7 ± 0.8* 20.7 ± 1.1* 
Mag-SiO2-Ca(3) CITR NPs 15.5 ± 1.0* 21.8 ± 0.7* 
 
 
Table 21. Trypan blue exclusion test. MS1 cell mortality after direct contact of 72 hours with nanoparticles. 
Data are shown as the mean ± standard deviation (n = 4). *P < 0.05 compared with control. 
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Figure 54. Optical microscopic images of endothelial cells (MS1 cells) after direct contact with MNPs (2 
and 20 µg/ml) for 24 hours. Magnification: 20x, bar scale = 50 µm. No effects are observed on cell 
morphological features. 
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Figure 55. Optical microscopic images of endothelial cells (MS1 cells) after direct contact with MNPs (2 
and 20 µg/ml) for 48 hours. Magnification: 20x, bar scale = 50 µm. No effects are observed on cell 
morphological features. 
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Figure 56. Optical microscopic images of endothelial cells (MS1 cells) after direct contact with MNPs (2 
and 20 µg/ml) for 48 hours. Magnification: 20x, bar scale = 50 µm. No effects are observed on cell 
morphological features. 
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4.3.7 Cells morphology evaluation by fluorescent microscopy 
No cellular morphological alterations were observed between cells in direct contact with MNPs and 
control using IF staining (Figures 57-59). These results confirmed that MNPs had not adverse 
effects on the cytoskeleton and cell morphology. 
 
 
Figure 57. Cells seeded for 24 h in contact with magnetic nanoparticles (2 and 20 µg/ml). IF staining with 
DAPI (blue) and phalloidin (red). Magnification: 20x, bar scale = 50 µm. 
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Figure 58. Cells seeded for 48 h in contact with magnetic nanoparticles (2 and 20 µg/ml). IF staining with 
DAPI (blue) and phalloidin (red). Magnification: 20x, bar scale = 50 µm. 
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Figure 59. Cells seeded for 72 h in contact with magnetic nanoparticles (2 and 20 µg/ml). IF staining with 
DAPI (blue) and phalloidin (red). Magnification: 20x, bar scale = 50 µm. 
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4.3.8 ROS generation induced by MNPs 
 
Naked and silica core-shell type iron oxide nanoparticles could induce the generation of 
intracellular reactive oxygen species (ROS) depending on the concentration of nanoparticles, and 
oxidative stress followed by ROS generation may cause damage to mitochondria and DNA. We 
investigated whether Mag and Mag-SiO2, Mag-SiO2-Ca(3) CITR and IDR NPs could induce the 
generation of intracellular ROS. CellROX Green Reagent was used to determine the generation of 
intracellular ROS induced by MNPs. 
ROS generation was observed in MS1 cells exposed to Mag and Mag-SiO2, Mag-SiO2-Ca(3) CITR 
and Mag-SiO2-Ca(3) IDR NPs at 2 and 20 µg/ml concentrations for 24 h (Fig. 60). An increase in 
ROS generation was observed in a concentration-dependent manner i.e., 3.75%, 20.04% of ROS 
expression following the exposure of 2 and 20 µg/ml of Mag NPs, respectively after 24 hours; 
2.6%, 13.17% following the exposure of 2 and 20 µg/ml of Mag-SiO2 NPs; 11.88%, 20.41% 
following the exposure of 2 and 20 µg/ml of Mag-SiO2-Ca(3) CITR NPs and 1.01% and 9.52% 
following the exposure of 2 and 20 µg/ml of Mag-SiO2-Ca(3) IDR NPs respectively after 24 hours. 
All data were considered statistically significant (p < 0.05). 
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Figure 60. Effect of MNPs on the generation of ROS. Cells were treated with a designated concentration of 
MNPs for 24 hours. Results are expressed as mean ± SD. *P < 0.05 compared with control untreated and 
positive control (Menadione 25 µM). **P < 0.05 compared with positive control (Menadione 25 µM). 
 
4.3.9 Apoptosis and necrosis 
To further verify the apoptosis process induced by MNPs, Annexin-V/PI double staining was 
carried out. Annexin V (aV) which is easily reacted with phosphatidylserine (PS) was used as a 
marker of apoptosis. Propidium iodide (PI), which was utilized to detect plasma membrane 
integrity, was employed to detect necrotic cell death [103].  Statistical data were extracted from the 
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pseudo-color dot plot using CellQuest software, based on the percentage of aV−/PI− (viable cells), 
aV−/PI+ (necrotic cells), aV+/PI− (apoptotic cells), and aV+/PI+  (late apoptotic cells). The data on 
MS1 cells  from the annexin-V staining experiment are summarized in Fig. 61. Compared to  the 
negative control group, the percentage of viable cells is similar. MS1 cells did not undergo 
apoptosis following incubation with MNPs. Flow cytometry demonstrated that treatment with 
MNPs for 24, 48 and 72 h did not significantly increase the numbers of apoptotic cells compared to 
control cells. The lower left quadrant represents the living cells, and the upper right quadrant shows 
the late apoptotic cells, while the lower right quadrant shows the early apoptotic cells in the 
scatterplot of bivariate flow cytometry (Figures 62-64). The percentage of apoptotic cells after 
direct contact with MNPs was in a range between: 3.74% and 5.56% for 2 µg/ml and 3.31% and 
6.3% for 20 µg/ml respectively after 24 hours; 1.29% and 5.7% for 2 µg/ml and 4.44% and 6.05% 
for 20 µg/ml respectively after 48 hours; 28.19% and 30.31% for 2 µg/ml and 31.29% and 36.4% 
for 20 µg/ml respectively after 72 hours, compared to 4.16% ± 0.45% at 24 h; 2.05% ± 0.24% at 48 
h and 25.25% ± 1.86% for control cells (P < 0.05; Figures 62-64). 
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Figure 61. The percentages of apoptosis and necrosis of MS1 cells after the incubation with two 
concentrations of MNPs: 2 and 20 µg/ml for 24, 48 and 72 h at 37 °C. Values were the means ± SD. * P < 
0.05 versus control cells. 
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Figure 62. Representative graphs of apoptosis evaluation after 24 hours using Flow cytometry. 
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Figure 63. Representative graphs of apoptosis evaluation after 48 hours using Flow cytometry. 
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Figure 64. Representative graphs of apoptosis evaluation after 72 hours using Flow cytometry. 
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4.3.10 Direct contact cytotoxicity in dynamic conditions 
The toxicity of MNPs in dynamic conditions was assessed using two different assays: LDH assay 
and XTT assay. In fact, a comparison between results of two independent assays should provide a 
higher level of confidence when quantifying toxic effects in dynamic conditions. As first result, it 
was assumed that the MNPs volumetric concentrations in static and dynamic conditions are 
comparable because we did not observe a significant decrease in MNPs media concentration after 2 
h, 12 h and 24 h of circulation in the fluidic system. A recent report on gravitational sedimentation 
of MNPs in a cuvette by Alexander et al. (2013) [113] showed that small MNPs did not deposit in 
significant amounts over 24 h. The same experiment was reproduced with Mag and Mag-SiO2 
nanoparticles confirming this result (data not shown). 
Using dynamic conditions of cell culture, the cells morphology appeared typically elongated. MS1 
cells showed a cell viability in dynamic conditions comparable to control. Cell viability ranged 
between 86% and 97% in XTT assay for Mag and Mag-SiO2 NPs. LDH release was in a range 
between 2.77 and 3.56% for Mag NPs and between 2.59 and 3.98% for Mag-SiO2 NPs. LDH 
cytotoxicity assay confirmed the same trend of XTT assay (Tables 22-23). Data from XTT assay 
were considered statistically significant (p < 0.05). FESEM and EDS analyses showed Mag 
nanoparticles adsorbed onto the MS1 cell membrane. Instead Mag-SiO2 NPs adsorption was not 
observed onto cells (Fig. 65).  
 
LDH release (% of total) 
Stimulation  Mag NPs Mag-SiO2 NPs Control 
2 h  2.77 ± 0.39 % 2.59 ± 0.28% 2.24 ± 0.41% 
12 h  3.19 ± 0.46% 3.04 ± 0.35% 2.48 ± 0.30% 
24 h  3.56 ± 0.51% 3.98 ± 0.46% 2.74 ± 0.37% 
 
Table 22. Effect on MS1 cell-membrane integrity following exposure to MNPs in dynamic conditions. Data 
are shown as the mean ± standard deviation. 
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XTT assay 
Stimulation  Mag NPs Mag-SiO2 NPs Control 
2 h  93.8 ± 4.2% 96.9 ± 3.7% 100% 
12 h  89.5 ± 2.8%* 93.1 ± 3.3% 100% 
24 h  86.8 ± 3.1%* 90.9 ± 2.7% 100% 
 
Table 23. MS1 cell viability following exposure to MNPs in dynamic conditions; XTT assay. Data are 
shown as the mean ± standard deviation *P < 0.05 compared with control.  
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Figure 65. FESEM images and EDS spectrum of MS1 cells on polycaprolactone in dynamic conditions. 
Only Mag nanoparticles were adsorbed onto the MS1 cell membrane. 
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4.3.11 Macroscopic evaluation of organs 
 
No death was after injection of either Mag or Mag-SiO2 NPs either for doses of 2 and 20 mg Fe/kg. 
Mice showed no anorexia, lethargy, and lusterless skin symptoms. After 7 days, animals were 
euthanized and autopsied for both types and doses of MNPs and control. The autopsy revealed 
many organ alterations in animals injected with 20 mg Fe/kg Mag-SiO2: splenomegaly, bleeding in 
lymph nodes and hepatomegaly (Table 24). No organ alterations were observed for 2 mg Fe/kg for 
both Mag and Mag-SiO2 NPs in comparison with the control (Table 25). 
 
 
 
Organ Mag NPs Mag-SiO2 NPs Control 
Liver 1,69 + 0,07 g 1,79 + 0,12 g 1,68 + 0,08 g 
Spleen 122,5 + 12,4 mg 275,2 + 38,7 mg 91,5 + 18,7 mg 
Left Kidney 136,5 + 33,2 mg 144,5 + 38,9 mg 126 + 22,6 mg 
Right Kidney 146,5 + 36,5 mg 158 + 39,9 mg 132,2 + 19,7 mg 
Brain 439,7 + 9,1 mg 436,5 + 16,3 mg 433,2 + 12,1 mg 
Lung 142,2 + 12,5 mg 146,7 + 18,1 mg 138,2 + 14,3 mg 
Heart 163 + 45,5 mg 166,7 + 41,8 mg 158 + 51,6 mg 
 
Table 24. Organ weights after MNPs injection at the dose of 20 mg Fe/kg. Data are shown as the mean ± 
standard deviation (n = 3). In red the most relevant alterations. 
 
 
Organ Mag NPs Mag-SiO2 NPs Control 
Liver 1,37 + 0,18 g 1,23 + 0,22 g 1,46 + 0,07 g 
Spleen 94 + 12,9 mg 102 + 6,4 mg 100,3 + 15,5 mg 
Left Kidney 151,5 + 20,8 mg 144,5 + 22,2 mg 176,8 + 8,3 mg 
Right Kidney 165,2 + 27,5 mg 164,5 + 36,8 mg 177,5 + 4,2 mg 
Brain 421,5 + 41,3 mg 415 + 52,5 mg 441,5 + 18,3 mg 
Lung 157,5 + 11,1 mg 166,8 + 6,5 mg 170 + 7,4 mg 
Heart 167 + 29,7 mg 157,8 + 37,8 mg 173,8 + 8,2 mg 
 
Table 25. Organ weights after MNPs injection at the dose of 2 mg Fe/kg. Data are shown as the mean ± 
standard deviation (n = 3). 
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4.3.12 Hematological parameters evaluation 
MNPs stabilized with silica coatings have been evaluated for safety following i.v. injection into 
mice using two doses: 2 and 20 mg Fe/kg. For the dose of 20 mg Fe/kg different alterations were 
observed for serum biomarkers and hematological parameters in particular for Mag-SiO2 NPs 
respect to Mag NPs (Tables 26 and 27). In addition, these alterations for Mag-SiO2 NPs (20 mg 
Fe/kg) were also reported in the histological sections and in ICP-AES measurement, as indicated 
below. However for both concentrations there was no death after injection of either Mag or Mag-
SiO2 at a dose of 20 mg/kg and all mice showed no anorexia, lethargy, and lusterless skin 
symptoms. Instead for the concentration of 2 mg Fe/kg although a bit of the injected nanoparticles 
accumulated in the liver and spleen at 7 days post injection, such accumulation did not result in any 
notable or long-term alteration of hematological parameters and serum biomarker levels such as 
alanine aminotransferase, aspartate aminotransferase, creatinine and lactic acid dehydrogenase, 
which are indicative of the liver functionality (Tables 28 and 29). Hematological parameters and 
serum biomarkers altered were considered statistically significant (p < 0.05). 
 
 Control Mag NPs Mag-SiO2 NPs 
Red blood cell (10
6
/μl) after 3 days  8.77 + 1.07 8.86 + 0.91 8.52 + 1.12 
Red blood cell (10
6
/μl) after 7 days  8.74 + 1.13 8.93 + 1.15 8.44 + 1.31 
White blood cell (10
3
/μl) after 3 days  6.50 + 1.48 6.85 + 2.03 7.70 + 1.71* 
White blood cell (10
3
/μl) after 7 days  6.47 + 1.66 6.93 + 1.48 7.81 + 1.57* 
 
Table 26. Hematological parameters in the mice groups injected with MNPs at concentrations of 20 mg 
Fe/kg in mice. Data are shown as the mean ± standard deviation. In red the most relevant alterations. *P < 
0.05 compared with control. 
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 Control Mag NPs Mag-SiO2 NPs 
ALT (U/l)  39.89 + 3.63 41.78 + 3.26 48.4 + 2.04* 
AST (U/l)  128.54 + 13.41 132.81 + 8.11 147.58 + 15.01* 
CRE (μmol/l)  19.6 + 1.32 20.33 + 1.52 25.96 + 1.35* 
LDH (U/l)  837.67 + 80.43 849.77 + 88.91 908.07 + 87.08* 
 
Table 27. Serum biomarker levels in the mice groups injected with MNPs at concentrations of 20 mg Fe/kg 
in mice. Data are shown as the mean ± standard deviation. In red the most relevant alterations. *P < 0.05 
compared with control. 
 
 
 Control Mag NPs Mag-SiO2 NPs 
Red blood cell (10
6
/μl) after 3 days  9.83 + 0.52  9.76 + 0.93  9.71 + 1.19  
Red blood cell (10
6
/μl) after 7 days  9.75 + 0.83  9.69 + 1.07  9.64 + 0.71  
White blood cell (10
3
/μl) after 3 days  6.51 + 0.73  6.63 + 1.18  6.72 + 1.26  
White blood cell (10
3
/μl) after 7 days  6.57 + 1.14  6.73 + 1.22  6.88 + 1.61  
 
Table 28. Hematological parameters in the mice groups injected with MNPs at concentrations of 2 mg Fe/kg 
in mice. Data are shown as the mean ± standard deviation. In red the most relevant alterations. 
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 Control Mag NPs Mag-SiO2 NPs 
ALT (U/l)  39.42 + 2.69 43.15 + 2.72 44.26 + 2.06* 
AST (U/l)  127.35 + 12.07 129.34 + 7.12 134.81 + 6.83 
CRE (μmol/l)  19.21 + 1.25 21.91 + 1.03 23.48 + 1.47* 
LDH (U/l)  833.75 + 53.28 841.67 + 57.91 843.46 + 46.35 
 
Table 29. Serum biomarker levels in the mice groups injected with MNPs at concentrations of 2 mg Fe/kg in 
mice. Data are shown as the mean ± standard deviation. *P < 0.05 compared with control. 
 
4.3.13 Iron uptake quantification 
 
To quantify the nanoparticles uptaking in major organs, the iron content was measured by ICP-
AES. Iron uptake was higher in liver in 2 mg Fe/kg Mag-SiO2 group compared to Mag group and 
control. Iron uptake in 2 mg Fe/kg MNPs groups in other organs was comparable to that of control 
(Fig. 66 and Table 30). Data recorded in 20 mg Fe/kg MNPs presented high variability but 
generally the iron was mainly accumulated in liver and spleen (p < 0.05) (Fig. 67 and Table 31). 
No accumulation was observed in kidney, brain, lung and heart. Therefore in 20 mg Fe/kg group the 
organ were for iron accumulation as follows: 1) spleen, 2) liver, 3) heart, 4) lung, 5) kidney and 6) 
brain. In 20 mg Fe/kg Mag-SiO2 group spleens accumulated more iron than those of Mag group (p 
< 0.05).   
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Figure 66. Iron uptake in different organs 7 days post-injection as measured by ICP-AES. The injection dose 
was 2 mg of Fe/kg in 300 µl of saline. Data are shown as the mean ± standard deviation (n = 3). *P < 0.05 
compared with control. 
 
 
 
 Mag NPs Mag-SiO2 NPs  Control 
Liver 190,03 + 12,45 µg Fe/g 174,47 + 22,59 µg Fe/g 162,40 + 10,70 µg Fe/g 
Spleen 1042,54 + 125,57 µg Fe/g* 1286,42 + 152,08 µg Fe/g* 864,71 + 169,24 µg Fe/g 
Kidney 231,55 + 63,93 µg Fe/g 206,13 + 48,48 µg Fe/g 203,66 + 31,08 µg Fe/g 
Brain 79,68 + 11,17 µg Fe/g 61,81 + 9,81 µg Fe/g 79,69 + 10,63 µg Fe/g 
Heart 416,33 + 36,40 µg Fe/g* 430,22 + 69,10 µg Fe/g* 529,17 + 32,02 µg Fe/g 
Lung 463,04 + 42,37 µg Fe/g 436,64 + 29,53 µg Fe/g 359,11 + 34,88 µg Fe/g 
 
Table 30. Concentration of iron in different organs 7 days post-injection (2 mg Fe/kg) as measured by ICP-
AES (the unit of measurement is expressed in μg g-1 wet tissue). Data are shown as the mean ± standard 
deviation (n = 3). *P < 0.05 compared with control. 
 
 
110 
 
 
Figure 67. Iron uptake in different organs 7 days post-injection as measured by ICP-AES. The injection dose 
was 20 mg of Fe/kg in 300 µl of saline. Data are shown as the mean ± standard deviation (n = 3). *P < 0.05 
compared with control. 
 
 
 
 Mag NPs Mag-SiO2 NPs  Control 
Liver 817,1 + 285,25 µg Fe/g*  751,0 + 161,89 µg Fe/g* 302,14 + 81,88 µg Fe/g 
Spleen 3990,6 + 1123,52 µg Fe/g* 4563,9 + 1233,98 µg Fe/g* 2404,4 + 369,99 µg Fe/g 
Kidney 412,7 + 109,67 µg Fe/g 472,4 + 134,19 µg Fe/g 443,8 + 140,62 µg Fe/g 
Brain 173,6 + 18,23 µg Fe/g 166,9 + 68,80 µg Fe/g 244,3 + 24,10 µg Fe/g 
Heart 706,3 + 60,15 µg Fe/g 814,0 + 282,52 µg Fe/g 707,9 + 207,48 µg Fe/g 
Lung 821,0 + 267,6 µg Fe/g 577,80 + 194,61 µg Fe/g 780,44 + 385,95 µg Fe/g 
 
Table 31. Concentration of iron in different organs 7 days post-injection (20 mg Fe/kg) as measured by ICP-
AES (the unit of measurement is expressed in μg g-1 wet tissue). Data are shown as the mean ± standard 
deviation (n = 3). *P < 0.05 compared with control. 
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4.3.14 Histological evaluation of iron accumulation (20 mg Fe/kg) 
To deeply investigate the iron accumulation in the tissues, the Perls’ Prussian blue staining of major 
organs was performed using MNPs (Mag and Mag-SiO2) at the concentrations of 2 and 20 mg 
Fe/kg. Iron (Fe
2+
 and Fe
3+
) was observed as intense blue signals in liver and spleen and seldom in 
the kidney for both MNPs when injected at the concentration of 20 mg Fe/kg (Figures 68 and 69). 
No iron accumulation was observed in kidney, brain, lung and heart. 
  
 
Figure 68. Representative images of Prussian blue stained histological tissue section of organs (liver, spleen 
and kidney) (MNPs 20 mg Fe/kg). The blue circles indicate iron deposits within tissue. Magnification: 40x, 
bar scale = 20 µm. 
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Figure 69. Representative images of Prussian blue stained histological tissue section of organs (lung, heart 
and brain) (MNPs 20 mg Fe/kg). Magnification: 40x, bar scale = 20 µm. 
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4.3.15 Histological evaluation of iron accumulation (2 mg Fe/kg) 
 
In this group (2 mg Fe/kg) iron deposits were seldom observed in liver, spleen and kidney (Figures 
70 and 71) and never in the brain, lung and heart. 
 
 
Figure 70. Representative images of Prussian blue stained histological tissue section of organs (liver, spleen 
and kidney) (MNPs 2 mg Fe/kg). The blue circles indicate iron deposits within tissue. Magnification: 40x, 
bar scale = 20 µm.  
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Figure 71. Representative images of Prussian blue stained histological tissue section of organs (lung, heart 
and brain) (MNPs 2 mg Fe/kg). Magnification: 40x, bar scale = 20 µm. 
 
 
 
 
 
115 
 
4.4 Discussion 
The improvement of physicochemical properties of the third synthesis of MNPs was fundamental to 
produce stable magnetic nanoparticles as far as colloidal stability and dispersibility properties were 
concerned. The third synthesis of MNPs was produced using citric acid only for 3 hours as 
dispersant agent and washing extensively with water using an ultrafiltration device. Furthermore, 
the third synthesis of MNPs was produced to improve cytocompatibility of calcium-silica coated 
iron-oxide nanoparticles compared to the second synthesis. 
The overall objective of this work was to screen MNPs within a set of standard assays commonly 
used by nanotoxicological evaluation and then determine the effect of flow on toxicity by exposing 
MS1 cells to MNPs in a bioreactor.   
To reach this goal, we first characterised each MNP in DMEM cell culture medium, than we tested 
them in standard static conditions using a certain concentration. In static conditions apoptosis and 
ROS production by MS1 cells were also investigated. MS1 cells in contact with MNPs of last group 
showed a small percentage of apoptotic and necrotic cells. ROS are important intracellular 
mediators of the inflammatory response and cell death following uptake of nanoparticles. In fact 
cytotoxicity of MNPs can be triggered by ROS generation due to the release of metal ions and 
surface crystal defects [114-116]. Accumulation of ROS results in a loss of homeostatic 
mechanisms in cells, and then oxidative stress appears if the cell cannot sweep the generated ROS, 
and it may cause damage to mitochondria and DNA [117, 118].   
For this reason, ROS generation induced by third synthesis of MNPs on MS1 cells was investigated. 
Naked and silica core-shell type iron-oxide nanoparticles could induce the generation of 
intracellular ROS depending on the concentration of nanoparticles. In fact, ROS generation induced 
by third synthesis of MNPs was in a concentration-dependent manner. The levels of ROS induced 
by third synthesis of MNPs on MS1 cells were not so high respect to untreated control. This effect 
could be due to a lower physiological production of ROS by MS1 murine endothelial cells because 
they are able to withstand to the particular conditions of oxygen pressure (pO2) in the blood vessels 
[119].   
Afterwards we compared the MNPs for testing in dynamic conditions demonstrating that even the 
application of gentle flow didn’t change the susceptibility of cells to toxic insult from nanoparticles. 
Moreover, cytocompatibility of third synthesis of MNPs in dynamic conditions by using a 
continuous flow bioreactor was carried out to simulate the flow of MNPs injected in a blood vessel 
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and reproduce the conditions more similar to an in vivo clinical situation. In the following, this 
experimental approach was further extended by evaluating the effects of in vivo toxicity of 
nanoparticles and by monitoring all vital, haematological and enzymatic parameters of mice used 
for the experiments of biodistribution of MNPs to have a complete view of possible toxic effects of 
MNPs.  
The in vivo experiments showed that SiO2 coated NPs, when injected at the dose of 20 mg Fe/kg, 
were toxic causing splenomegaly, bleeding in lymph nodes and hepatomegaly. Iron accumulation 
was mainly concentrated in liver and spleen in 20 mg Fe/kg Mag-SiO2 NPs group. In contrast no 
macroscopic organ alteration was observed for 20 mg Fe/kg Mag NPs even if iron accumulation 
was observed in liver and spleen. Using doses ten-fold less (2 mg Fe/kg), no clinical signs of 
toxicity were observed for both Mag and Mag-SiO2 NPs. Isolated sporadic iron accumulation were 
observed histologically only in liver, spleen and kidney. 
 
4.5 Conclusions 
The cytocompatibility of MNPs is multifactorial and depends upon their composition, 
physicochemical properties, dose and cellular model used for characterization. The dynamic in vitro 
tests were carried out like a first step aimed at mimicking the in vivo situation, in which MNPs 
interact with cells under a tangential flow. The MNPs described in this chapter were demonstrated 
to be cytocompatible in not direct contact cell model and in both static and dynamic cell models 
suggesting a promising feasibility for applications in biomedicine. However, the in vivo 
experiments showed that SiO2 coated NPs, when injected at 20 mg Fe/kg, were toxic. All together 
these data suggest that magnetic nanoparticles are promising tools for biomedicine, especially if 
used at the appropriate dose and chemical composition. The in vivo data confirmed a good 
performance of the nanoparticles using a concentration of 2 mg Fe/kg body weight. This new 
synthesis of core-shell calcium doped MNPs was important to reduce their toxic effects respect to 
the previous synthesis and give the possibility of surface functionalization.  
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5. Concluding remarks 
In this PhD project three sequential syntheses of magnetic nanoparticles were prepared by 
improving their physical-chemical, colloidal properties and cytocompatibility with the aim to reach 
the best preparation of stable MNPs to be used in biomedicine. 
The first synthesis of MNPs were flawed by rapid precipitation and consequent clusters formation 
affecting cytocompatibility. For this reason, a colloidal stabilizer in the synthesis procedure of 
nanoparticles, the citric acid, was then introduced.   
Calcium-silica core-shell type iron-oxide nanoparticles were developed with the aim to offer a 
positively charged surface available for functionalization. These MNPs were characterized to 
investigate their cytocompatibility. Colloidal stability but unsuitable cytocompatibility in particular 
as far as of Mag-SiO2-Ca(3) NPs and Mag-SiO2-Ca(17) NPs were regarded.  
Finally improving the inclusion method and stabilization of Ca
2+
 ions in the silica shell, the 
cytocompatibility was enhanced and the materials were addressable to in-vivo application.  
The tools developed in this thesis spanned a range of physical-chemical, biological and magnetic 
aspects and incorporate innovations on a nanometric range of scales. MNP-based technologies 
appear to hold a significant potential for a myriad of biomedical applications and the toxic potential 
of MNPs cannot be overlooked. For this reason we carried out different physical-chemical and 
biological characterization of MNPs to identify a safe dose and formulation of MNPs. 
Understanding the relationship between the physicochemical properties of MNP constructs and 
their behavior will induce full translational potential of these nanoparticles. The magnetic 
nanoparticles could be in future one of the field with higher perspectives of development for 
different scientific applications, especially such as a smart targeted drug delivery platform for in 
vivo disease therapies. 
 
Acknowledgments 
I would like to express my gratitude to my supervisor Prof. ssa Lia Rimondini. Her constant 
support, stimulating suggestions and encouragement helped me in research work. It was a great 
pleasure for me to conduct this thesis under her supervision.  
118 
 
I want to thank Prof.ssa Antonia Follenzi and Associazione Italiana Ricerca Cancro (AIRC) to 
support my fellowship during these three years of PhD.  
Moreover, I would like to thank COST Action MP1005 (NAMABIO) and Prof. Saša Novak for 
support for STSM program at Jožef Stefan Institute, Ljubljana, Slovenia. 
I would like to express my honest and sincere regards to Dr. Andrea Cochis for his kind help. 
Finally, I would like to thank Prof.ssa Enrica Vernè and Dr. Marta Miola for synthesis and 
physicochemical characterization of magnetic nanoparticles. 
 
References 
 
1. Zoraida PA. Nanomaterials for medical applications. Springdale, Elsevier 2013; 1-32. 
2. Poon W, Zhang X, Nadeau J. Nanoparticle drug formulations for cancer diagnosis and 
treatment. Crit Rev Oncog 2014; 19:223-45. 
3. Kreuter J. Nanoparticles-based drug delivery system. J Cont Rel 1991; 16:169-176. 
4. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine 2015; 
10:975-999. 
5. Euliss LE, DuPont JA, Gratton S, DeSimone J. Imparting size, shape, and composition 
control of materials for nanomedicine. Chem Soc Rev 2006; 35:1095-1104. 
6. Wennerstrom H, Linman B. Micelles. Physical chemistry of surfactant association. Rev Sec 
Phys Lett 1979; 52:1-86. 
7. Nelson PH, Rutledge GC, Hatton TA. On the size and shape of self-assembled micelles. J 
Chem Phys 1997; 107:10777-10781. 
8. Duncan R, Vicent MJ, Greco F, Nicholson RI. Polymer-drug conjugates: towards a novel 
approach for the treatment of endocrine-related cancer. Endocr Relat Cancer 2005; 12:S189-
S199. 
9. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for targeting cancer. 
Trends Biotechnol 2006; 24:39-47. 
119 
 
10. Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochim Pol 
2001; 48: 199-208. 
11. Sigh P. Dendrimers and their applications in immunoassays and clinical diagnosis. 
Biotechnol Appl Biochem 2007; 48:1-9. 
12. Kobayashi H, Kawamoto S, Jo SK, Bryant HL, Brechbiel MW, Star RA. Macromolecular 
MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and 
cores. Bioconjug Chem 2003; 14:388-394. 
13. Gillies ER, Fréchet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov 
Today 2005; 10:35-43. 
14. Wu G, Barth RF, Yang W, Chatterjee M, Tjarks W, Ciesielski MJ, et al. Site-specific 
conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody 
cetuximab (IMC-C225) and its evaluation as potential delivery agent for neutron capture 
therapy. Bioconjug Chem 2004; 15:185-194. 
15. Dufès C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 
2005; 57:2177-2202. 
16. Oliveira JM, Salgado AJ, Sousa N, Mano JF, Reis RL. Dendrimers and derivatives as 
potential therapeutic tool in regenerative medicine strategies-a review. Prog Polym Sci 
2010; 35:1163-1194. 
17. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of 
drug-loaded polymeric nanoparticles. Nanomedicine 2006; 2:8-21. 
18. Pecher J, Mecking S. Nanoparticles from step-growth coordination polymerization. 
Macromolecules 2007; 40:7733-7735. 
19. Hittinger E, Kokil A, Weder C. Synthesis and characterization of cross-linked conjugated 
polymer milli-, micro-, and nanoparticles. Angew Chem Int Ed 2004; 43:1808-1811. 
20. Stoeva S, Klabunde KJ, SorensenCM, Dragieva I. Gram-scale synthesis of monodisperse 
gold colloids by the solvated metal atom dispersion method and digestive ripening and their 
organization into two- and three-dimensional structures. J Am Chem Soc 2002; 124:2305-
2311. 
21. Uccello-Barretta G, Evangelisti C, Balzano F, Vanni L, Aiello F, Jicsinszky L. Water 
soluble heptakis(6-deoxy-6-thio)cyclomaltoheptaose capped gold nanoparticles via metal 
vapour synthesis: NMR structural characterization and complexation properties. Carbohydr 
Res 2011; 346:753-758. 
120 
 
22. Špringer T, Ermini ML, Špačková B, Jabloňků J, Homola J. Enhancing sensitivity of surface 
plasmon resonance biosensors by functionalized gold nanoparticles: size matters. Anal 
Chem 2014; 86:10350-10356. 
23. Bedford EE, Spadavecchia J, Pradier CM, Gu FX. Surface plasmon resonance biosensors 
incorporating gold nanoparticles. Macromol Biosci 2012; 12:724-739. 
24. Alivisatos AP. Semiconductor clusters, nanocrystals, and quantum dots. Science 1996; 271: 
933-937. 
25. Murray CB, Kagan CR, Bawendi MG. Synthesis and characterization of monodisperse 
nanocrystals and close-packed nanocrystal assemblies. Annual Review of Materials 
Research 2000; 30:545-610. 
26. Bruchez M, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as 
fluorescent biological labels. Science 1988; 281:2013-2016. 
27. Michalet X, Pinaud F, Lacoste TD, Dahan M, Bruchez M. Properties of fluorescent 
semiconductor nanocrystals and their applications to biological labelling. Single Mol 2001; 
2:261-276. 
28. Rosenthal SJ, Tomlinson I, Adkins EM, Schroeter S, Adams S, Swafford L, et al. Targeting 
cell surface receptors with ligand-conjugated nanocrystals. J Am Chem Soc 2002; 124: 
4586-4594. 
29. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, et al. Immunofluorescent labeling 
of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat 
Biotechnol 2003; 21:41-46. 
30. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for 
biomedical applications. Biomaterials 2005; 26:3995-4021. 
31. Hofmann-Amtenbrink M, von Rechenberg B, Hofmann H. Nanostructured Materials for 
Biomedical Applications. Transworld Research Network 2009; 5:119-149 
32. Huber DL. Synthesis, properties, and applications of iron nanoparticles. Small Weinh 
Bergstr Ger 2005; 1:482-501. 
121 
 
33. Lu CW, Hung Y, Hsiao JK, Yao M, Chung TH, Lin YS, Wu SH, Hsu SC, Liu HM, Mou 
CY, et al. Bifunctional magnetic silica nanoparticles for highly efficient human stem cell 
labeling. Nano Lett 2007; 7:149-154. 
34. Balakrishnan S, Bonder M. Particle size effect on phase and magnetic properties of polymer-
coated magnetic nanoparticles. J Magn Magn Mater 2009; 321:117-122. 
35. Peng S, Xie J, Sun S. Synthesis of Co/MFe(2)O(4) (M = Fe, Mn) Core/Shell nanocomposite 
particles. J Solid State Chem 2008; 181:1560-1564. 
36. Emad G, Mohamed W, Atef O, Lokeshwar B. Synthesis, magnetic and optical properties of 
core/shell Co1-xZnxFe2O4/SiO2 nanoparticles. Nanoscale Res Lett 2011; 6:460-468. 
37. Rohilla S, Kumar S, Aghamkar P, Sunder S. Investigations on structural and magnetic 
properties of cobalt ferrite/silica nanocomposites prepared by the coprecipitation method. J 
Mag Magn Mater 2011; 323:897-902. 
38. Baldi G, Bonacchi D, Innocenti C, Lorenzi G, Sangregorio C. Cobalt ferrite nanoparticles: 
The control of the particle size and surface state and their effects on magnetic properties. J 
Magn Magn Mater 2007; 311:10-16. 
39. Soleimani R, Soleimani M, Godarzi MG. Investigation of the thermal stability of Mn ferrite 
particles synthesized by a modified co-precipitation method. J Fusion Energ 2011; 30:338-
341. 
40. Kim DH, Nikles DE, Brazel CS. Synthesis and characterization of multifunctional chitosan - 
MnFe2O4 nanoparticles for magnetic hyperthermia and drug delivery. Materials 2010; 
3:4051-4065. 
41. Kim DH, Zeng H, Ng TC, Brazel CS. T1 and T2 relaxivities of succimer-coated MFe2
3+
O4 
(M=Mn
2+
, Fe
2+
 and Co
2+
 ) inverse spinel ferrites for potential use as phase-contrast agents in 
medical MRI. J Magn Magn Mater 2009; 321:3899-3904. 
42. Batoo KM. Study of dielectric and impedance properties of Mn ferrites. Physica B 2011; 
406:382-387. 
43. Vaidyanathan G, Sendhilnathan S, Arulmurugan R. Structural and magnetic properties of 
CoZnFe2O4 nanoparticles by co-precipitation method. J Magn Magn Mater 2007; 313:293-
299.  
44. Rath C, Anand S, Das RP, Sahu KK, Kulkarni SD, Date SK, et al. Dependence on cation 
distribution of particle size, lattice parameter, and magnetic properties in nanosize Mn-Zn 
ferrite. J Appl Phys 2002; 91:2211-2215. 
122 
 
45. Sharifi I, Shokrollahi H, Amiri S. Ferrite-based magnetic nanofluids used in hyperthermia 
applications. J Magn Magn Mater 2012; 324:903-915. 
46. Itoh H, Sugimoto T. Systematic control of size, shape, structure, and magnetic properties of 
uniform magnetite and maghemite particles. J Colloid Interface Sci 2003; 265:283-295. 
47. Wu JH, Ko SP, Liu HL, Kim S, Ju JS, Kim YK. Sub 5 nm magnetite nanoparticles: 
Synthesis, microstructure, and magnetic properties. Mater Lett 2007, 61, 3124-3129. 
48. Eckert CA, Knutson BL, Debenedetti PG. Supercritical fluids as solvents for chemical and 
materials processing. Nature 1996; 383:313-318. 
49. Lee CS, Lee H, Westervelt RM. Microelectromagnets for the control of magnetic 
nanoparticles. Appl Phys Lett 2001; 79:3308-3310.  
50. Mathur S, Barth S, Werner U, Hernandez-Ramirez F, Romano-Rodriguez A. Chemical 
vapor growth of one-dimensional magnetite nanostructures. Adv Mater 2008; 20:1550-1554. 
51. Narayanan KB, Sakthivel N. Biological synthesis of metal nanoparticles by microbes. Adv 
Colloid Interface Sci 2010; 156:1-13. 
52. Hulkoti NI, Taranath TC. Biosynthesis of nanoparticles using microbes - a review. Colloids 
Surf B Biointerfaces 2014; 121:474-483. 
53. Mohanraj S, Kodhaiyolii S, Rengasamy M, Pugalenthi V. Green synthesized iron oxide 
nanoparticles effect on fermentative hydrogen production by Clostridium acetobutylicum. 
Appl Biochem Biotechnol 2014; 173:318-331. 
54. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and 
characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. 
Chem Rev 2012; 112:5818-5878. 
55. Weissleder R, Moore A, Mahmood U, et al. In vivo magnetic resonance imaging of 
transgene expression. Nat Med 2000; 6:351-355. 
56. Bulte JW, Douglas T, Witwer B, Zhang SC, et al. Magnetodendrimers allow endosomal 
magnetic labeling and in vivo tracking of stem cells. Nat. Biotechnol 2001; 19:1141-1147. 
123 
 
57. Kircher MF, Allport JR, Graves EE, Love V, Josephson L, Lichtman AH, Weissleder R. In 
vivo high resolution three-dimensional imaging of antigenspecific cytotoxic T-lymphocyte 
trafficking to tumors. Cancer Res 2003; 63:6838-6846. 
58. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 
3:16-20. 
59. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in 
biomedicine. J Phys Appl Phys 2003; 36:r167-r181. 
60. Duguet E, Vasseur S, Mornet S, et al. Magnetic nanoparticles and their applications in 
medicine. Nanomed 2006; 1:157-168. 
61. Soenen SJ, De Cuyper M. Assessing iron oxide nanoparticle toxicity in vitro: current status 
and future prospects. Nanomedicine (Lond) 2010; 5:1261-1275. 
62. Clift MJD, Boyles MSP, Brown DM, Stone V. An investigation into the potential for 
different surface-coated quantum dots to cause oxidative stress and affect macrophage cell 
signalling in vitro. Nanotoxicology  2010; 4:139-149. 
63. Thanh NTK, Green LAW. Functionalisation of nanoparticles for biomedical applications. 
Nano Today 2010; 5:213-230. 
64. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 
2010; 6:12-21. 
65. Mironava T, Hadjiargyrou M, Simon M, Jurukovski V, Rafailovich MH. Gold nanoparticles 
cellular toxicity and recovery: effect of size, concentration and exposure time. 
Nanotoxicology  2010; 4:120-137. 
66. Lanone S, Rogerieux F, Geys J, Dupont A, Maillot-Marechal E, Boczkowski J, Lacroix G, 
Hoet P. Comparative toxicity of 24 manufactured nanoparticles in human alveolar epithelial 
and macrophage cell lines. Part Fibre Toxicol 2009; 6:14-26. 
67. Monteiro-Riviere NA, Inman AO, Zhang LW. Limitations and relative utility of screening 
assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl 
Pharmacol 2009; 234:222-235. 
68. Pfaller T, Colognato R, Nelissen I, Favilli F, Casals E, Ooms D, et al. The suitability of 
different cellular in vitro immunotoxicity and genotoxicity methods for the analysis of 
nanoparticle-induced events. Nanotoxicology  2010; 4:52-72. 
124 
 
69. Carlson C, Hussain SM, Schrand AM, Braydich-Stolle LK, Hess KL, Jones RL, Schlager JJ. 
Unique cellular interaction of silver nanoparticles: Size-dependent generation of reactive 
oxygen species. J Phys Chem B 2008; 112:13608-13619. 
70. Gurr J-R, Wang ASS, Chen C-H, Jan K-Y. Ultrafine titanium dioxide particles in the 
absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. 
Toxicology 2005; 213:66-73. 
71. Karlsson HL, Cronholm P, Gustafsson J, Möller L. Copper oxide nanoparticles are highly 
toxic: A comparison between metal oxide nanoparticles and carbon nanotubes. Chem Res 
Toxicol 2008; 21:1726-1732. 
72. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science 2006; 
311:622-627. 
73. Ahamed M, Alhadlaq HA, Alam J, Khan MA, Ali D, Alarafi S. Iron oxide nanoparticle-
induced oxidative stress and genotoxicity in human skin epithelial and lung epithelial cell 
lines. Curr Pharm Des 2013; 19:6681-6690. 
74. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 
47:65-81. 
75. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of 
drugs across the blood-brain barrier. J Pharm Sci 1998; 87:1305-1307. 
76. Ferrari M. Cancer Nanotechnology: Opportunities and Challenges. Nat Rev Cancer 2005; 
5:161-171. 
77. Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI. 
Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS 
Nano 2008; 2:889-896. 
78. Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu T, Tan W. Nanotechnology in 
therapeutics: a  focus on nanoparticles as a drug delivery system. Nanomedicine (Lond) 
2012; 7:1253-71. 
79. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. 
Handb Exp Pharmacol 2010; 197:3-53.  
80. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR 
effect in macromolecular therapeutics: a review. J Control Release 2000; 65:271-284. 
125 
 
81. Maxwell DJ, Bonde J, Hess DA, Hohm SA, et al. Fluorophore-conjugated iron oxide 
nanoparticle labeling and analysis of engrafting human hematopoietic stem cells. Stem Cells 
2008; 26:517-524. 
82. Tucker BA, Rahimtula M, Mearow KM. A procedure for selecting and culturing 
subpopulations of neurons from rat dorsal root ganglia using magnetic beads. Brain Res 
Brain Res Protoc 2005; 16:50-57. 
83. McCarthy JR, Kelly KA, Sun EY, Weissleder R, et al. Targeted delivery of multifunctional 
magnetic nanoparticles. Nanomed 2007; 2:153-167. 
84. Weber C, Falkenhagen D. Specific blood purification by means of antibody-conjugated 
magnetic microspheres. in: U. Hafeli, et al., (Eds.), Scientific and Clinical Applications of 
Magnetic Carriers, Plenum Press, New York, 1997; 371-378. 
85. Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive 
detection of proteins. Science 2003; 301:1884-1886. 
86. L pez-L pez MT, Durán JD , Delgado AV,  onzález-Caballero F. Stability and magnetic 
characterization of oleate-covered magnetite ferrofluids in different nonpolar carriers. J 
Colloid Interface Sci 2005; 291:144-151. 
87. Fuller KJ, Issels RD, Slosman DO, Guillet JG, Soussi T, Polla BS. Cancer and the heat-
shock response. Eur J Cancer 1994; 30A:1884-1891. 
88. Harmon BV, Takano YS, Winterford CM, Gobe GC. The role of apoptosis in the response 
of cells and tumours to mild hyperthermia. Int J Radiat Biol 1991; 59:489-501. 
89. Chatterjee DK, Diagaradjane P, Krishnan S. Nanoparticle-mediated hyperthermia in cancer 
therapy. Ther Deliv 2011; 2:1001-1014.  
90. Jordan A, Scholz R, Wust P, et al. Endocytosis of dextran and silan-coated magnetite 
nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma 
cells in vitro. J Magn Magn Mater 1999; 194:185-196. 
91. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic 
nanoparticles. J Biosci Bioeng 2005; 100:1-11.  
92. Krotz F, Sohn HY, Gloe T, Plank C, Pohl U. Magnetofection potentiates gene delivery to 
cultured endothelial cells. J Vas Res 2003; 40:425-434. 
126 
 
93. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, Gansbacher B, Plank 
C. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in 
vivo. Gene Ther 2002; 9:102-109. 
94. Griffith LG, Naughton G. Tissue engineering-current challenges and expanding 
opportunities. Science 2002; 295:1009-1014. 
95. Santo VE, Rodrigues MT, Gomes ME. Contributions and future perspectives on the use of 
magnetic nanoparticles as diagnostic and therapeutic tools in the field of regenerative 
medicine. Expert Rev Mol Diagn 2013; 13:553-566. 
96. Ito H, Kato R, Ino K, Honda H. Magnetic manipulation device for the optimization of cell 
processing conditions. J Biosci Bioeng 2010; 109:182-188. 
97. Yamamoto Y, Ito A, Fujita H, Nagamori E, Kawabe Y, Kamihira M. Functional evaluation 
of artificial skeletal muscle tissue constructs fabricated by a magnetic force-based tissue 
engineering technique. Tissue Eng Part A 2011; 17:107-114. 
98. Gould P. Nanomagnetism shows in vivo potential. Nano Today 2006; 1:34-39. 
99. Qiao RR, Yang CH, Gao MY. Superparamagnetic iron oxide nanoparticles: from 
preparations to in vivo MRI applications. J Mater Chem 2009; 19:6274-6293. 
100. Schwarz S, Wong JE, Bornemann J, Hodenius M, Himmelreich U, Richtering W, 
Hoehn M, Zenke M, Hieronymus T. Polyelectrolyte coating of iron oxide nanoparticles for 
MRI-based cell tracking. Nanomed Nanotechnol 2012; 8:682-691. 
101. Li Z, Kawashita M, Araki N, Mitsumori M, Hiraoka M, Doi M. Magnetite 
nanoparticles with high heating efficiencies for application in the hyperthermia of cancer. 
Mater Sci Eng C 2010; 30:990-996. 
102. Stöber W, Fink A. Controlled growth of monodisperse silica spheres in the micron 
size range. J Colloid Interface Sci 1968; 26:62-69. 
103. Yu C, Zhou Z, Wang J, Sun J, Liu W, Sun Y, Kong B, Yang H, Yang S. In depth 
analysis of apoptosis induced by silica coated manganese oxide nanoparticles in vitro. J 
Hazard Mater 2015; 283:519-528. 
104. Park EJ, Choi DH, Kim Y, Lee EW, Song J, Cho MH, Kim JH, Kim SW. Magnetic 
iron oxide nanoparticles induce autophagy preceding apoptosis through mitochondrial 
damage and ER stress in RAW264.7 cells. Toxicol In Vitro 2014; 28:1402-1412. 
127 
 
105. Deng YH, Wang CC, Hu JH, Yang WL, Fu SK. Investigation of formation of silica-
coated magnetite nanoparticles via sol-gel approach. Colloids and Surfaces A: Physiochem 
Eng Aspects 2005; 262:87-93 
106. Men HF, Liu HQ, Zhang ZL, et al. Synthesis, properties and application research of 
atrazine Fe3O4-SiO2 magnetic molecularly imprinted polymer. Environ Sci Pollut Res Int 
2012; 19:2271-2280. 
107. Singh RK, Kim TH, Patel KD, Knowles JC, Kim HW. Biocompatible magnetite 
nanoparticles with varying silica-coating layer for use in biomedicine: physicochemical and 
magnetic properties, and cellular compatibility. J Biomed Mater Res A 2012; 100:1734-
1742. 
108. Shubayev VI, Pisanic TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug 
Deliv Rev 2009; 61:467-477. 
109. Robert JH. Zeta Potential in Colloid Science: Principles and Applications. Colloid 
Sciences Series, Sydney. Academic Press 1989; 1-38. 
110. Jasper R, Locatelli GO, Pilati C, Locatelli C. Evaluation of biochemical, 
hematological and oxidative parameters in mice exposed to the herbicide glyphosate-
Roundup. Interdiscip Toxicol 2012; 5:133-40. 
111. Stefánsson A, Gunnarsson I, Giroud N. New methods for the direct determination of 
dissolved inorganic, organic and total carbon in natural waters by reagent-free ion 
chromatography and inductively coupled plasma atomic emission spectrometry. Anal Chi 
Acta 2007; 582:69-74.  
112. Mermet JM. Is it still possible, necessary and beneficial to perform research in ICP-
atomic emission spectrometry? J Ana At Spectrom 2005;  20:11-16. 
113. Alexander CM, Dabrowiak JC, Goodisman J. Gravitational sedimentation of gold 
nanoparticles. J Colloid Interface Sci 2013; 396:53-62. 
114. Lovric J, Cho SJ, Winnik FM, Maysinger D. Unmodified cadmium telluride quantum 
dots induce reactive oxygen species formation leading to multiple organelle damage and cell 
death. Chem Bio 2005; 12:1227-1234. 
128 
 
115. Karlsson HL, Cronholm P, Gustafsson J, Moller L. Copper oxide nanoparticles are 
highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes. Chem 
Res Toxicol 2008; 21:1726-1732.  
116. Yan DH, Yin GF, Huang ZB, Li L, Liao XM, Chen XC, Yao YD, Hao BQ. Cellular 
compatibility of biomineralized ZnO nanoparticles based on prokaryotic and eukaryotic 
systems. Langmuir 2011; 27:13206-13211. 
117. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science 
2006; 311:622-627. 
118. Zhu MT, Feng WY, Wang Y, Wang B, Wang M, Ouyang H, Zhao YL, Chai ZF. 
Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide 
nanoparticles in rats and the potential health risk assessment. Toxicol Sci 2009; 107:342-
351. 
119. Kapitulnik J, Benaim C, Sasson S. Endothelial cells derived from the blood-brain 
barrier and islets of Langerhans differ in their response to the effects of bilirubin on 
oxidative stress under hyperglycemic conditions. Front Pharmacol 2012; 3:131-136. 
 
 
 
